第94回日本泌尿器科学会総会賞

2006.4   一般社団法人　日本泌尿器科学会  

The first detailed annual record on the National Clinical Database Urology Division in Japan: A report on five surgical procedures. Reviewed

Kikuchi E, Yamamoto H, Yasui T, Hatakeyama S, Mizuno R, Sakamoto S, Mizuno K, Morizane S, Hayakawa N, Kobayashi T, Kamoto T, Eto M:

Int J Urol   31 ( 12 )   1344 - 1355   2024.12

Optimization of Extended Pelvic Lymph Node Dissection Side for Prostate Cancer. Reviewed

Shiota M, Shimbo M, Tsukahara S, Tanegashima T, Mutaguchi J, Goto S, Kobayashi S, Matsumoto T, Hattori K, Endo F, Eto M:

Ann Surg Oncol   31 ( 13 )   8986 - 8992   2024.12

Annual record on the number of general urological surgeries registered in the National Clinical Database system between April 2018 and December 2021 in Japan. Reviewed

Yasui T, Kikuchi E, Yamamoto H, Ishii D, Mizuno R, Hatakeyama S, Kobayashi T, Uchida J, Takahashi M, Sakamoto S, Morizane S, Kamoto T, Eto M:

Int J Urol   31 ( 11 )   1256 - 1262   2024.11

Efficacy of robot-assisted partial nephrectomy compared to conventional laparoscopic partial nephrectomy for completely endophytic renal tumor: a multicenter, prospective study. Reviewed

Hinata N, Murakami S, Nakano Y, Hara I, Kondo T, Hamamoto S, Shiroki R, Nagayama J, Kawakita M, Eto M, Ukimura O, Takenaka A, Takagi T, Shimbo M, Azuma H, Yoshida T, Furukawa J, Kawamorita N, Fujisawa M:

Int J Clin Oncol   29 ( 10 )   1548 - 1556   2024.10

Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients. Reviewed

Tanegashima T, Shiota M, Tsukahara S, Mutaguch J, Goto S, Kobayashi S, Matsumoto T, Eto M:

Prostate   84 ( 14 )   1329 - 1335   2024.10

Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement. Reviewed

Tanegashima T, Shiota M, Kimura T, Takamatsu D, Matsui Y, Yokomizo A, Saito R, Morizane S, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Edamura K, Narita S, Yamaguchi T, Kasahara T, Hashimoto K, Kato M, Yoshino T, Akamatsu S, Matsukawa A, Kaneko T, Matsumoto R, Joraku A, Kato M, Saito T, Kato T, Tatarano S, Sakamoto S, Kanno H, Terada N, Nishiyama N, Kitamura H, Eto M; Japanese Urological Oncology Group:

Int J Clin Oncol   29 ( 10 )   1586 - 1593   2024.10

Regression and growth rates in androgen deprivation therapy for advanced castration-sensitive prostate cancer. Reviewed

Blas L, Shiota M, Matsuyama H, Kamoto T, Enokida H, Fujimoto N, Sakai H, Igawa T, Kamba T, Yokomizo A, Naito S, Eto M:

World J Urol   42 ( 1 )   604 - 604   2024.10

Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project. Reviewed

Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, Yoshino T, Nonomura N:

World J Urol   42 ( 1 )   526 - 526   2024.9

The Omission of Upfront Treatment Intensification Does Not Adversely Affect Oncological Outcomes in a Subset of Castration-Highly Sensitive Metastatic Prostate Cancer. Reviewed

Fujimoto N, Nagata Y, Shiota M, Minato A, Tomisaki I, Harada K, Eto M, Miyamoto H:

In Vivo   38 ( 5 )   2328 - 2334   2024.9

Predictive model of castration resistance in advanced prostate cancer by machine learning using genetic and clinical data: KYUCOG-1401-A study. Reviewed

Shiota M, Nemoto S, Ikegami R, Tatarano S, Kamoto T, Kobayashi K, Sakai H, Igawa T, Kamba T, Fujimoto N, Yokomizo A, Naito S, Eto M:

BJC Rep   2 ( 1 )   69 - 69   2024.9

Independent validation of genetic risk model to progression after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer. Reviewed

Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Tanegashima T, Eto M:

Int J Urol   31 ( 8 )   945 - 947   2024.8

Functional outcomes in robot-assisted partial nephrectomy with three-dimensional images reconstructed from computed tomography: a propensity score-matched comparative analysis. Reviewed

Kobayashi S, Tsukino K, Mutaguchi J, Tanegashi T, Goto S, Matsumoto T, Shiota M, Eto M:

J Robot Surg   18 ( 1 )   314 - 314   2024.8

Papillary renal neoplasm with reverse polarity has low frequency of alterations in chromosomes 7, 17, and Y. Reviewed

Kiyozawa D, Iwasaki T, Takamatsu D, Kohashi K, Miyamoto T, Fukuchi G, Eto M, Yamashita M, Oda Y:

Virchows Arch   485 ( 2 )   299 - 306   2024.8

Clinical practice guidelines for telesurgery 2022 : Committee for the promotion of remote surgery implementation, Japan Surgical Society. Reviewed

Mori M, Hirano S, Hakamada K, Oki E, Urushidani S, Uyama I, Eto M, Ebihara Y, Kawashima K, Kanno T, Kitsuregawa M, Kinugasa Y, Kobayashi J, Nakamura H, Noshiro H, Mandai M, Morohashi H:

Surg Today   54 ( 8 )   817 - 828   2024.8

Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer. Reviewed

Shiota M, Ushijima M, Tsukahara S, Nagakawa S, Okada T, Tanegashima T, Kobayashi S, Matsumoto T, Eto M:

Free Radic Biol Med   221   81 - 88   2024.8

Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer. Reviewed

Blas L, Shiota M, Tanegashima T, Kobayashi S, Matsumoto T, Eto M:

Int J Urol   31 ( 7 )   829 - 831   2024.7

Comparisons of in-hospital fee and surgical outcomes between robot-assisted, laparoscopic, and open radical cystectomy: a Japanese nationwide study. Reviewed

Yokoyama M, Chen W, Waseda Y, Fujiwara M, Kato D, Shirakawa T, Shimizu Y, Nenohi T, Matsumoto Y, Okumura T, Urushibara M, Ai M, Fushimi K, Fukagai T, Eto M, Fujii Y, Ishizaka K:

Jpn J Clin Oncol   54 ( 7 )   822 - 826   2024.7

Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. Reviewed

Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Grünwald V, Burgents J, Xie R, McKenzie J, Powles T:

Eur Urol   86 ( 1 )   4 - 9   2024.7

Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study. Reviewed

Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, Takamatsu D, Oda Y, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M:

J Immunol   213 ( 1 )   23 - 28   2024.7

Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort. Reviewed

Kato M, Shiota M, Kimura T, Hanazawa R, Hirakawa A, Takamatsu D, Tashiro K, Matsui Y, Hashine K, Saito R, Yokomizo A, Yamamoto Y, Narita S, Hashimoto K, Matsumoto H, Akamatsu S, Nishiyama N, Eto M, Kitamura H, Tsuzuki T; Japanese Urological Oncology Group:

Int J Urol   31 ( 6 )   662 - 669   2024.6

Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy. Reviewed

Shiota M, Takamatsu D, Matsui Y, Yokomizo A, Morizane S, Saito R, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Narita S, Edamura K, Yamaguchi T, Hashimoto K, Kato M, Kasahara T, Yoshino T, Akamatsu S, Kaneko T, Matsukawa A, Matsumoto R, Joraku A, Saito T, Kato T, Kato M, Enokida H, Sakamoto S, Terada N, Kanno H, Nishiyama N, Kimura T, Kitamura H, Eto M; Japanese Urological Oncology Group:

Ann Surg Oncol   31 ( 6 )   3872 - 3879   2024.6

Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of Japan. Reviewed

Nakanishi S, Fukushima Y, Inokuchi J, Hakariya T, Kakinoki H, Enokida H, Chikui K, Matsuoka H, Shin T, Mukai S, Kamba T, Eto M, Imamura R, Noguchi M, Igawa T, Haga N, Kamoto T, Fujimoto N, Saito S:

Int J Urol   31 ( 5 )   484 - 491   2024.5

Steroids-producing nodules: a two-layered adrenocortical nodular structure as a precursor lesion of cortisol-producing adenoma. Reviewed

Fukumoto T, Umakoshi H, Iwahashi N, Ogasawara T, Yokomoto-Umakoshi M, Kaneko H, Fujita M, Uchida N, Nakao H, Kawamura N, Matsuda Y, Sakamoto R, Miyazawa T, Seki M, Eto M, Oda Y, Suzuki Y, Ogawa S, Ogawa Y:

EBioMedicine   103   105087 - 105087   2024.5

TAS0313 Plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma. Reviewed

Nishiyama H, Yonese J, Kawahara T, Matsumoto R, Miyake H, Matsubara N, Uemura H, Eto M, Azuma H, Obara W, Terai A, Fukasawa S, Suekane S:

Mol Cancer Ther   23 ( 4 )   532 - 540   2024.4

Field experiment of a telesurgery system using a surgical robot with haptic feedback. Reviewed

Ota M, Oki E, Nakanoko T, Tanaka Y, Toyota S, Hu Q, Nakaji Y, Nakanishi R, Ando K, Kimura Y, Hisamatsu Y, Mimori K, Takahashi Y, Morohashi H, Kanno T, Tadano K, Kawashima K, Takano H, Ebihara Y, Shiota M, Inokuchi J, Eto M, Yoshizumi T, Hakamada K, Hirano S, Mori M:

Surg Today   54 ( 4 )   375 - 381   2024.4

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Reviewed

Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators:

J Clin Oncol   42 ( 11 )   1222 - 1228   2024.4

Clinical features and oncological outcomes of bladder cancer microsatellite instability. Reviewed

Nagakawa S, Shiota M, Takamatsu D, Tsukahara S, Mastumoto T, Blas L, Inokuchi J, Oda Y, Eto M:

Int J Urol   31 ( 4 )   438 - 445   2024.4

Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy. Reviewed

Blas L, Shiota M, Tanegashima T, Tsukahara S, Ueda S, Mutaguchi J, Goto S, Kobayashi S, Matsumoto T, Inokuchi J, Eto M:

Int J Urol   31 ( 4 )   404 - 408   2024.4

GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401. Reviewed

Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higasijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, Naito S:

Int J Urol   31 ( 4 )   362 - 369   2024.4

The Role of Adipocytokines and their Receptors in Prostate Cancer: Adiponectin May Protect Against Progression.

Kashiwagi E, Kawahara T, Kinoshita F, Shiota M, Inokuchi J, Miyamoto H, Eto M:

Anticancer Res   44 ( 4 )   1369 - 1376   2024.4

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial. Reviewed

Grünwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, Zanetta S, Keizman D, Suárez C, Négrier S, Lee JL, Santini D, Bedke J, Staehler M, Kollmannsberger C, Choueiri TK, Motzer RJ, Burgents JE, Xie R, Okpara CE, Powles T:

Int J Cancer   156 ( 7 )   1326 - 1335   2024.4

Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project. Reviewed

Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, Yoshino T, Nonomura N:

BJC Rep   2 ( 1 )   28 - 28   2024.4

Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). Reviewed International journal

Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, Shinohara N, Uemura H:

Int J Urol   2024.3

Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer. Reviewed

Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group:

Int J Clin Oncol   30 ( 3 )   551 - 558   2024.3

Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab. Reviewed International journal

Blas L, Shiota M, Tsukahara S, Nagakawa S, Matsumoto T, Eto M:

Clin Genitourin Cancer   2024.2

Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy to the prostate. Reviewed International journal

Shiota M, Tsukahara S, Takamatsu D, Tanegashima T, Ueda S, Blas L, Goto S, Kobayashi S, Matsumoto T, Inokuchi J, Shioyama Y, Eto M:

Asian J Endosc Surg   2024.1

Comparative analyses of tumour immune microenvironment between collecting duct carcinoma and fumarate hydratase-deficient renal cell carcinoma. Reviewed International journal

Kiyozawa D, Kohashi K, Takamatsu D, Umekita S, Eto M, Kinjo M, Nishiyama K, Taguchi K, Oshiro Y, Kuboyama Y, Oda Y:

J Clin Pathol   2024.1

Differential cancer-specific survival with curative radiotherapy to the prostate for metastatic prostate cancer according to estimated survival by risk group. Reviewed International journal

Shiota M, Terada N, Kimura T, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group (JUOG):

Int J Urol   2023.12

Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation. Reviewed International journal

Shiota M, Tsukahara S, Ueda S, Mutaguchi J, Goto S, Kobayashi S, Matsumoto T, Blas L, Monji K, Inokuchi J, Eto M:

J Robot Surg   2023.12

Comprehensive investigation of clinicopathological and immunological features to determine prognostic impact in metastatic renal cell carcinoma: The JEWEL study. Reviewed International journal

Ohba K, Monji K, Osawa T, Yamana K, Yasuda Y, Tanaka H, Nakagawa Y, Fukuyama T, Matsubara N, Uemura H, Sakai H, Eto M:

Int J Urol   2023.11

Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment. Reviewed International journal

Minami K, Osawa T, Kojima T, Hara T, Eto M, Takeuchi A, Nakai Y, Ueda K, Ozawa M, Uemura M, Ohba K, Tamura K, Shindo T, Nakagomi H, Takahashi A, Anai S, Yokomizo A, Morizane S, Kimura T, Shimazui T, Miyauchi Y, Mitsuzuka K, Hara H, Yoshimura K, Shiina H, Ito YM, Murai S, Nishiyama H, Shinohara N, Kitamura H; Japanese Urological Oncology Group:

Urol Oncol   2023.11

Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment. Reviewed International journal

Blas L, Shiota M, Matsumoto T, Hori Y, Nakamura M, Seki N, Kuroiwa K, Yokomizo A, Morokuma F, Kiyoshima K, Eto M:

Int J Urol   2023.11

NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide. Reviewed International journal

Shiota M, Ushijima M, Tsukahara S, Nagakawa S, Blas L, Takamatsu D, Kobayashi S, Matsumoto T, Inokuchi J, Eto M:

Drug Resist Updat   2023.9

Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial. Reviewed International journal

Rha SY, Choueiri TK, Matveev VB, Alyasova A, Hong SH, Gordoa TA, Gurney H, Bjarnason GA, Buchler T, Pedrazzoli P, Takagi T, Park SH, Lee JL, Perini RF, He CS, McKenzie JA, Eto M:

Int J Cancer   2023.9

Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies. Reviewed International journal

Kashiwagi E, Shiota M, Inokuchi J, Tsukahara S, Imada K, Monji K, Goto S, Matsumoto T, Eto M:

Anticancer Res   2023.9

T1a Renal Cell Carcinoma With Metastasis: Japanese Society of Renal Cancer Retrospective Multi-institute Results. Reviewed International journal

Kato T, Wang C, Masumori N, Yamasaki T, Matsumoto H, Baba M, Ito K, Kimura T, Kitamura H, Takahashi M, Hongo F, Hasine K, Eto M, Ikeda JI, Nonomura N, Shinohara N:

Anticancer Res   2023.9

Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study. Reviewed International journal

Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC Investigators:

Int J Urol   2023.9

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Reviewed International journal

Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK:

Front Oncol   2023.8

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. Reviewed International journal

Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M, Hutson T, Motzer R, Winquist E, Maroto P, Keam B, Procopio G, Wong S, Melichar B, Rolland F, Oya M, Rodriguez-Lopez K, Saito K, McKenzie J, Porta C:

Eur Urol Oncol   2023.8

Virtual reality environments to train soft skills in medical and nursing education: a technical feasibility study between France and Japan. Reviewed International journal

Le Duff M, Michinov E, Bracq MS, Mukae N, Eto M, Descamps J, Hashizume M, Jannin P:

Int J Comput Assist Radiol Surg   2023.8

Telesurgery and telesurgical support using a double-surgeon cockpit system allowing manipulation from two locations. Reviewed International journal

Oki E, Ota M, Nakanoko T, Tanaka Y, Toyota S, Hu Q, Nakaji Y, Nakanishi R, Ando K, Kimura Y, Hisamatsu Y, Mimori K, Takahashi Y, Morohashi H, Kanno T, Tadano K, Kawashima K, Takano H, Ebihara Y, Shiota M, Inokuchi J, Eto M, Yoshizumi T, Hakamada K, Hirano S, Mori M:

Surg Endosc   2023.8

Real-world treatment outcomes of patients with penile cancer in the Kyushu-Okinawa area of Japan in the pre-guideline era. Reviewed International journal

Yamaguchi T, Goya M, Higashijima K, Tobu S, Sato R, Tatarano S, Mukai S, Uemura KI, Tatsugami K, Tsubouchi K, Shida Y, Ishii T, Sakai H, Matsuoka H, Haga N, Eto M, Igawa T, Kamoto T, Enokida H, Shin T, Noguchi M, Fujimoto N, Saito S, Kamba T:

Jpn J Clin Oncol   2023.8

Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men. Reviewed International journal

Blas L, Shiota M, Tsukahara S, Goto S, Kinoshita F, Matsumoto T, Monji K, Kashiwagi E, Inokuchi J, Eto M:

Int J Urol   2023.7

Reliability, validity, and responsiveness of the Japanese version of the EORTC QLQ-ELD14 in evaluating the health-related quality of life of elderly patients with cancer. Reviewed International journal

Kinoshita Y, Izukura R, Kishimoto J, Kanaoka M, Fujita H, Ando K, Nagai S, Akiyoshi S, Tagawa T, Kubo M, Inokuchi J, Ohuchida K, Oki E, Tanaka K, Eto M, Yoshizumi T, Nakamura M, Chishaki A:

J Cancer Res Clin Oncol   2023.7

Adverse Events of Abiraterone Acetate vs Enzalutamide. Reviewed International journal

Blas L, Shiota M, Tsukahara S, Nagakawa S, Matsumoto T, Eto M:

Urol Pract   2023.7

Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study. Reviewed International journal

Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Sekine Y, Kimura H, Narita S, Terada N, Momozawa Y, Akamatsu S, Habuchi T, Yokomizo A, Naito S, Eto M:

Endocr Relat Cancer   2023.6

Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial. Reviewed International journal

Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators:

Cancer Immunol Immunother   2023.6

Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis. Reviewed International journal

Lee JL, Desai C, Park SH, Tsuchiya N, Su PJ, Chan TTW, Gurney H, Gao S, Wang J, Sandner R, di Pietro A, Eto M:

Urol Oncol   2023.5

Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features. Reviewed International journal

Takamatsu D, Kiyozawa D, Kohashi K, Kinoshita F, Toda Y, Ishihara S, Eto M, Oda Y:

Pathol Res Pract   2023.4

Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors. Reviewed International journal

Shiota M, Akamatsu S, Sekine Y, Kimura H, Narita S, Fujimoto N, Terada N, Blas L, Habuchi T, Kamoto T, Momozawa Y, Eto M:

Cancer Sci   2023.4

A Phase Ii Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- And Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer. Reviewed International journal

Shiota M, Inoue R, Tashiro K, Kobayashi K, Horiyama S, Kanji H, Eto M, Egawa S, Haginaka J, Matsuyama H:

J Clin Pharmacol   2023.4

Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy. Reviewed International journal

Lee K, Shiota M, Takamatsu D, Ushijima M, Blas L, Okabe A, Kajioka S, Goto S, Kinoshita F, Matsumoto T, Monji K, Kashiwagi E, Inokuchi J, Oda Y, Eto M:

Int J Urol   2023.4

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Reviewed International journal

Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Méndez-Vidal MJ, Tjulandin S, Hoon Park S, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grünwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Alonso Gordoa T, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta CG:

Lancet Oncol   2023.3

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study. Reviewed International journal

Eto M, Takagi T, Kimura G, Fukasawa S, Tamada S, Miura Y, Oya M, Sassa N, Anai S, Nozawa M, Sakai H, Perini R, Yusa W, Ikezawa H, Narita T, Tomita Y:

Cancer Med   2023.3

Evaluation of bone density and skeletal muscle mass after sleeve gastrectomy using computed tomography method. Reviewed International journal

Kai K, Fujiwara T, Nagao Y, Oki E, Yoshizumi T, Eto M, Nakashima Y:

Bone Rep   2023.2

Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study. Reviewed International journal

Matsumoto T, Hori Y, Shiota M, Blas L, Nakamura M, Seki N, Kuroiwa K, Yokomizo A, Morokuma F, Kiyoshima K, Eto M:

Int J Urol   2023.2

Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study. Reviewed International journal

Tamada S, Nozawa M, Ohba K, Mizuno R, Takamoto A, Ohe C, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Kimura G, Tomita Y, Nonomura N, Eto M:

Int J Clin Oncol   2023.2

Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy. Reviewed International journal

Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group:

Int J Clin Oncol   2023.2

Validation of user-friendly models predicting extracapsular extension in prostate cancer patients. Reviewed International journal

Blas L, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:

Asian J Urol   2023.1

Prospective study of adoptive activated αβT lymphocyte immunotherapy for refractory cancers: development and validation of a response scoring system. Reviewed International journal

Nonami A, Matsuo R, Funakoshi K, Nakayama T, Goto S, Iino T, Takaishi S, Mizuno S, Akashi K, Eto M:

Cytotherapy   2023.1

2.5-mm articulated endoluminal forceps using a compliant mechanism. Reviewed International journal

Osawa K, Bandara DSV, Nakadate R, Nagao Y, Akahoshi T, Eto M, Arata J:

Int J Comput Assist Radiol Surg   2023.1

Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate. Reviewed International journal

Takahashi Y, Narita S, Shiota M, Miura M, Kagaya H, Kashima S, Yamamoto R, Nara T, Huang M, Numakura K, Saito M, Eto M, Habuchi T:

Eur J Clin Pharmacol   2023.1

Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy. Reviewed International journal

Blas L, Shiota M, Takamatsu D, Kinoshita F, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:

World J Urol   2023.1

IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. Reviewed International journal

Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N:

BMC Cancer   2022.12

Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer. Reviewed International journal

Kimura H, Mizuno K, Shiota M, Narita S, Terada N, Fujimoto N, Ogura K, Hatano S, Iwasaki Y, Hakozaki N, Ishitoya S, Sumiyoshi T, Goto T, Kobayashi T, Nakagawa H, Kamoto T, Eto M, Habuchi T, Ogawa O, Momozawa Y, Akamatsu S:

Br J Cancer   2022.11

Radical nephroureterectomy for UTUC conferred survival benefits irrespective of age and comorbidities. Invited Reviewed International journal

Teoh JY, Ng CF, Eto M, Chiruvella M, Capitanio U, Esen T, Zeng G, Lechevallier E, Andonian S, de la Rosette J:

World J Urol   2022.11

Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide. Reviewed International journal

Kashiwagi E, Shiota M, Lee K, Monji K, Naganuma H, Matsumoto T, Takeuchi A, Inokuchi J, Eto M:

JMA J   2022.10

Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer. Reviewed International journal

Kashiwagi E, Shiota M, Naganuma H, Monji K, Imada K, Lee K, Matsumoto T, Takeuchi A, Inokuchi J, Eto M:

Int J Urol   2022.10

Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients. Reviewed International journal

Igami K, Uchiumi T, Shiota M, Ueda S, Tsukahara S, Akimoto M, Eto M, Kang D:

Cancer Sci   2022.9

Robot-assisted partial nephrectomy with minimum follow-up of 5 years: A multi-center prospective study in Japan. Reviewed International journal

Furukawa J, Hinata N, Teisima J, Takenaka A, Shiroki R, Kobayashi Y, Kanayama HO, Hattori K, Horie S, Tozawa K, Kato M, Ohyama C, Habuchi T, Kawamorita N, Eto M, Fujisawa M:

Int J Urol   2022.9

Impact of nerve sparing in robot-assisted radical prostatectomy on the risk of positive surgical margin and biochemical recurrence. Reviewed International journal

Komori H, Blas L, Shiota M, Takamatsu D, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:

Int J Urol   2022.8

Noninvasive Diagnosis of the Mitochondrial Function of Doxorubicin-Induced Cardiomyopathy Using In Vivo Dynamic Nuclear Polarization-Magnetic Resonance Imaging. Reviewed International journal

Mizuta Y, Akahoshi T, Eto H, Hyodo F, Murata M, Tokuda K, Eto M, Yamaura K:

Antioxidants (Basel)   2022.7

Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer. Reviewed International journal

Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S, Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H; Japanese Urological Oncology Group:

Cancer Sci   2022.7

Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal Fibrosis. Reviewed International journal

Mukai S, Sakamoto N, Kakinoki H, Shibuya T, Moriya R, Nishihara K, Noguchi M, Shin T, Fujimoto N, Igawa T, Ishii T, Haga N, Enokida H, Eto M, Kamba T, Sakai H, Saito S, Terada N, Kamoto T:

J Clin Med   2022.6

Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer. Reviewed International journal

Yamashita T, Shiota M, Machidori A, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Shiga KI, Yokomizo A, Eto M:

Cancer Invest   2022.6

Artificial intelligence for segmentation of bladder tumor cystoscopic images performed by U-Net with dilated convolution. Reviewed International journal

Mutaguchi J, Morooka KI, Kobayashi S, Umehara A, Miyauchi S, Kinoshita F, Inokuchi J, Oda Y, Kurazume R, Eto M:

J Endourol   2022.6

A deep learning-based approach for the diagnosis of adrenal adenoma: a new trial using CT. Reviewed International journal

Kusunoki M, Nakayama T, Nishie A, Yamashita Y, Kikuchi K, Eto M, Oda Y, Ishigami K:

Br J Radiol   2022.6

Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Reviewed International journal

Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D:

Lancet Oncol   2022.6

医工連携で課題解決 - RAPNにおける超音波プローブアタッチメント開発 -. Reviewed International journal

小林　聡、中楯　龍、宮田信一、牟田口　淳、李　賢、門司恵介、柏木英志、武内在雄、塩田真己、猪口淳一、江藤正俊：

Jpn J Endourol Robot   2022.5

Validation of models predicting lymph node involvement probability in patients with prostate cancer. Reviewed International journal

Blas L, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Eto M:

Int J Urol   2022.5

An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer. Reviewed International journal

Ushijima M, Shiota M, Matsumoto T, Kashiwagi E, Inokuchi J, Eto M:

Cancer Sci   2022.5

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine. Reviewed International journal

Tsukahara S, Shiota M, Takamatsu D, Nagakawa S, Matsumoto T, Kiyokoba R, Yagi M, Setoyama D, Noda N, Matsumoto S, Hayashi T, Contreras-Sanz A, Black PC, Inokuchi J, Kohashi K, Oda Y, Uchiumi T, Eto M, Kang D:

Sci Rep   2022.5

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy. Reviewed International journal

Blas L, Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:

JMA J   2022.4

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer. Reviewed International journal

Yamada S, Shiota M, Blas L, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:

Prostate Int   2022.3

Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer. Reviewed International journal

Kobayashi M, Fujiyama N, Tanegashima T, Narita S, Yamamoto Y, Fujimoto N, Ueda S, Takeuchi A, Numakura K, Habuchi T, Matsuyama H, Eto M, Shiota M:

Cancer Immunol Immunother   2022.3

HLA Class I analysis provides insight into the genetic and epigenetic background of immune evasion in colorectal cancer with high microsatellite instability. Reviewed International journal

Kawazu M, Ueno T, Saeki K, Sax N, Togashi Y, Kaneseki T, Chida K, Kishigami F, Sato K, Kojima S, Otsuka M, Kawazoe A, Nishinakamura H, Maeda Y, Yamamoto Y, Yamashita K, Inoue S, Tanegashima T, Matsubara D, Tane K, Tanaka Y, Iinuma H, Hashiguchi Y, Hazama S, Khor SS, Tokunaga K, Tsuboi M, Niki T, Eto M, Shitara K, Torigoe T, Ishihara S, Aburatani H, Haeno H, Nishikawa H, Mano H:

Gastroenterology   2022.3

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer. Reviewed International journal

Chikamatsu S, Shiota M, Yamada S, Blas L, Matsumoto T, Kashiwagi E, Inokuchi J, Shiga KI, Yokomizo A, Eto M:

Prostate Int   2022.3

Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Reviewed International journal

Nakajima N, Miyajima A, Shinohara N, Obara W, Kondo T, Kimura G, Kume H, Fujimoto H, Sugiyama T, Nonomura N, Hongo F, Fukumori T, Takahashi M, Kanayama HO, Eto M:

Jpn J Clin Oncol   2022.3

Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy. Reviewed International journal

Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group:

Int J Clin Oncol   2022.2

T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma. Reviewed International journal

Harada M, Iida Y, Kotani H, Minami T, Komohara Y, Eto M, Yoshikawa K, Uemura H:

Cancer Immunol Immunother   2022.2

Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer. Reviewed International journal

Shiota M, Fujimoto N, Sekino Y, Tsukahara S, Nagakawa S, Takamatsu D, Abe T, Kinoshita F, Ueda S, Ushijima M, Matsumoto T, Kashiwagi E, Inokuchi J, Uchiumi T, Oda Y, Eto M:

Andrologia   2022.2

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis. Reviewed International journal

Tomita Y, Yamamoto Y, Tsuchiya N, Kanayama H, Eto M, Miyake H, Thomas P, Yoshida M, Koide Y, Umeyama Y, Pietro AD, Uemura H:

Int J Clin Oncol   2022.2

Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study. Reviewed International journal

Tamada S, Nozawa M, Ohba K, Mizuno R, Takamoto A, Ohe C, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Kimura G, Tomita Y, Nonomura N, Eto M:

Int J Clin Oncol   2022.2

Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy. Reviewed International journal

Blas L, Shiota M, Takamatsu D, Kinoshita F, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:

World J Urol   2022.1

Symptoms and noninvasive test parameters that clinically differentiate detrusor underactivity from bladder outlet obstruction without a pressure-flow-based diagnosis in men with lower urinary tract symptoms. Reviewed International journal

Takahashi R, Takei M, Namitome R, Yamaguchi O, Eto M:

Neurourol Urodyn   2022.1

Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients. Reviewed International journal

Kobayashi H, Shiota M, Sato N, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:

Anticancer Drugs   2022.1

Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer. Reviewed International journal

Shiota M, Blas L, Kobayashi S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:

Int J Urol   2022.1

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors. Reviewed International journal

Matsumoto T, Shiota M, Yamada S, Blas L, Naganuma H, Lee K, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:

JMA J   2022.1

2.5-mm articulated endoluminal forceps using a compliant mechanism. Reviewed International journal

Osawa K, Bandara DSV, Nakadate R, Nagao Y, Akahoshi T, Eto M, Arata J:

Int J Comput Assist Radiol Surg   2022.1

Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Reviewed International journal

Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay EA, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, Nishikawa H:

Sci Immunol   2021.11

Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer. Reviewed International journal

Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S:

Clin Cancer Res   2021.11

Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer. Reviewed International journal

Blas L, Ieiri K, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:

Anticancer Res   2021.11

The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study. Reviewed International journal

Nagakawa S, Shiota M, Fujimoto N, Yamamoto Y, Blas L, Tsukahara S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Matsuyama H, Eto M:

Urol Oncol   2021.10

Surveillance of urachal abscess in the Kyushu-Okinawa area of Japan. Reviewed International journal

Tobu S, Udo K, Nishihara K, Miyajima S, Ando T, Onizuka C, Itesako T, Ashikari A, Hakariya T, Igawa T, Tanaka M, Shin T, Kamoto T, Nakagawa M, Saito S, Sakai H, Eto M, Kamba T, Fujimoto N, Noguchi M:

Int J Urol   2021.10

Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. Reviewed International journal

Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M; Japanese Urological Oncology Group:

Cancer Sci   2021.9

Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. Reviewed International journal

Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K:

Cancer Immunol Immunother   2021.9

Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database. Reviewed International journal

Chikamatsu S, Shiota M, Onozawa M, Hinotsu S, Kitagawa Y, Sakamoto S, Kawai T, Eto M, Kume H, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):

Int J Urol   2021.9

Identification of Activated Protein Kinase Cα (PKCα) in the Urine of Orthotopic Bladder Cancer Xenograft Model as a Potential Biomarker for the Diagnosis of Bladder Cancer. Reviewed International journal

Kawano T, Tachibana Y, Inokuchi J, Kang JH, Murata M, Eto M:

Int J Mol Sci   2021.8

The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer. Reviewed International journal

Shiota M, Akamatsu S, Narita S, Sumiyoshi T, Fujiwara M, Uchiumi T, Ogawa O, Habuchi T, Eto M:

Pharmacogenomics J   2021.8

Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Reviewed International journal

Iwamoto C, Ohuchida K, Shinkawa T, Okuda S, Otsubo Y, Okumura T, Sagara A, Koikawa K, Ando Y, Shindo K, Ikenaga N, Nakata K, Moriyama T, Miyasaka Y, Ohtsuka T, Eto M, Akashi K, Nakamura M:

Cancer Lett   2021.8

Long-term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old. Reviewed International journal

Blas L, Onozawa M, Shiota M, Hinotsu S, Sakamoto S, Kitagawa Y, Kawai T, Eto M, Kume H, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):

Cancer Sci   2021.8

Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer. Reviewed International journal

Blas L, Shiota M, Yamada S, Ieiri K, Nagakawa S, Tsukahara S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:

Anticancer Res   2021.8

Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Reviewed International journal

Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S, Tanaka H, Koya N, Umebayashi M, Tsujimura K, Yew PY, Yoshimura S, Kiyotani K, Nakamura Y:

Anticancer Res   2021.8

Prognostic impact of prior local therapy in castration-resistant prostate cancer. Reviewed International journal

Koura M, Shiota M, Ueda S, Matsumoto T, Kobayashi S, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:

Jpn J Clin Oncol   2021.7

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study. Reviewed International journal

Matsumoto T, Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:

Prostate Int   2021.6

Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. Reviewed International journal

Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group.

J Geriatr Oncol   2021.6

Clinical advantages of robot-assisted partial nephrectomy versus laparoscopic partial nephrectomy in terms of global and split renal functions: A propensity score-matched comparative analysis. Reviewed International journal

Kobayashi S, Mutaguchi J, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Eto M:

Int J Urol   2021.6

Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors. Reviewed International journal

Machidori A, Shiota M, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Eto M:

Urol Oncol   2021.6

Morphological, immunohistochemical, and genomic analyses of papillary renal neoplasm with reverse polarity. Reviewed International journal

Kiyozawa D, Kohashi K, Takamatsu D, Yamamoto T, Eto M, Iwasaki T, Motoshita J, Shimokama T, Kinjo M, Oshiro Y, Yonemasu H, Oda Y:

Hum Pathol   2021.6

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer. Reviewed International journal

Shiota M, Fujimoto N, Matsumoto T, Tsukahara S, Nagakawa S, Ueda S, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Eto M:

Front Oncol   2021.5

Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database. Reviewed International journal

Shiota M, Sumikawa R, Onozawa M, Hinotsu S, Kitagawa Y, Sakamoto S, Kawai T, Eto M, Kume H, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):

Int J Urol   2021.5

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups. Reviewed International journal

Quinn DI, Ng CF, Grande E, Kwon TG, Linke R, Lee JL, Rosbrook B, Thakur MN, Eto M, Gross-Goupil M:

ESMO Open   2021.4

Robot-assisted partial nephrectomy versus standard laparoscopic partial nephrectomy for renal hilar tumor: A prospective multi-institutional study. Reviewed International journal

Hinata N, Shiroki R, Tanabe K, Eto M, Takenaka A, Kawakita M, Hara I, Hongo F, Ibuki N, Nasu Y, Teishima J, Kawai N, Kawauchi A, Kondo T, Kawamorita N, Oyama C, Horie S, Shimbo M, Kato M, Kanayama H, Koito Y, Fujisawa M; Japanese Society of Endourology:

Int J Urol   2021.4

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. Reviewed International journal

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators:

N Engl J Med   2021.4

Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Reviewed International journal

Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M, Urological Oncology Group Juog J:

Cancer Sci   2021.4

Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer. Reviewed International journal

Fujimoto N, Shiota M, Matsukawa T, Minato A, Tomisaki I, Ohnishi R, Eto M:

In Vivo   2021.3

Molecular detection of maturation stages in the developing kidney. Reviewed International journal

Naganuma H, Miike K, Ohmori T, Tanigawa S, Ichikawa T, Yamane M, Eto M, Niwa H, Kobayashi A, Nishinakamura R:

Dev Biol   2021.2

Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer. Reviewed International journal

Shiota M, Narita S, Habuchi T, Eto M:

Pharmacogenomics J   2021.2

Genomic characteristics revealed by targeted exon sequencing of testicular germ cell tumors in Japanese men. Reviewed International journal

Matsumoto T, Shiota M, Uchiumi T, Ueda S, Tsukahara S, Toshima T, Matsumoto S, Noda N, Eto M, Kang D:

Int J Urol   2021.1

Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. Reviewed International journal

Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, Masuda S, Okamoto I, Nakagawa T, Ito T, Eto M, Mori M, Nakanishi Y, Egashira N:

Sci Rep   2021.1

Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression. Reviewed International journal

Shiota M, Sekino Y, Tsukahara S, Abe T, Kinoshita F, Imada K, Ueda S, Ushijima M, Nagakawa S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Oda Y, Eto M:

Cancer Sci   2021.1

Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. Reviewed International journal

Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group.

J Geriatr Oncol   2020.12

The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study. Reviewed International journal

Tohi Y, Kato T, Matsumoto R, Shinohara N, Shiga K, Yokomizo A, Nakamura M, Kume H, Mitsuzuka K, Sasaki H, Egawa S, Matsumura M, Hashine K, Inokuchi J, Eto M, Baba H, Ichikawa T, Kinoshita H, Matsuda T, Kakehi Y, Sugimoto M:

Int J Clin Oncol   2020.12

The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation? Reviewed International journal

Ieiri K, Shiota M, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Iwai H, Shiga KI, Yokomizo A, Yoshitake T, Shioyama Y, Ishigami K, Terashima H, Eto M:

Urol Oncol   2020.12

Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide. Reviewed International journal

Shiota M, Machidori A, Abe T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Yokomizo A, Naito S, Eto M:

Int J Urol   2020.12

A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T-cell immunotherapy in advanced breast cancer. Reviewed International journal

Masuda T, Nonami A, Tanaka F, Ando Y, Eto M, Mimori K:

Breast J   2020.12

Corrigendum to: Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program. Reviewed International journal

Kume H, Homma Y, Shinohara N, Obara W, Kondo T, Kimura G, Fujimoto H, Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M:

Jpn J Clin Oncol   2020.12

Exosomes from adipose tissue-derived mesenchymal stem cells ameliorate histone-induced acute lung injury by activating the PI3K/Akt pathway in endothelial cells. Reviewed International journal

Mizuta Y, Akahoshi T, Guo J, Zhang S, Narahara S, Kawano T, Murata M, Tokuda K, Eto M, Hashizume M, Yamaura K:

Stem Cell Res Ther   2020.11

The SWI/SNF Chromatin-Remodeling Complex Status in Renal Cell Carcinomas With Sarcomatoid or Rhabdoid Features. Reviewed International journal

Kinoshita F, Kohashi K, Sugimoto M, Takamatsu D, Kiyozawa D, Eto M, Oda Y:

Virchows Arch   2020.11

Cross-continental comparison of safety and protection measures amongst urologists during COVID-19. Reviewed International journal

de la Rosette J, Laguna P, Álvarez-Maestro M, Eto M, Mochtar CA, Albayrak S, Mendoza-Valdes A, Ong TA, Khadgi S, Al-Terki A, Bolton D, Gomez R, Klotz L, Kulkarni S, Tanguay S, Gravas S; Société Internationale d’Urologie Board of Directors:

Int J Urol   2020.11

Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy. Reviewed International journal

Shiota M, Endo S, Fujimoto N, Tsukahara S, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Eto M:

Urol Oncol   2020.11

Effect of Smoking on Oncological Outcome among Prostate Cancer Patients after Radical Prostatectomy with Neoadjuvant Hormonal Therapy. Reviewed International journal

Sato N, Shiota M, Shiga KI, Kashiwagi E, Takeuchi A, Inokuchi J, Yokomizo A, Naito S, Eto M:

Cancer Invest   2020.11

Difficulty in differential diagnosis for renal cancer with microscopic papillary architecture: overlapped pathological features among papillary renal cell carcinoma (RCC), mutinous tubular and spindle cell carcinoma, and unclassified RCC. Lessons from a Japanese multicenter study. Reviewed International journal

Ito K, Mikami S, Kuroda N, Nagashima Y, Tatsugami K, Masumori N, Kondo T, Takagi T, Nakanishi S, Eto M, Kamba T, Tomita Y, Matsuyama H, Tsushima T, Nakazawa H, Oya M, Kimura G, Shinohara N, Asano T:

Jpn J Clin Oncol   2020.10

Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision. Reviewed International journal

Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H:

Int J Urol   2020.9

High-throughput Screen Identifies 5-HT Receptor as a Modulator of AR and a Therapeutic Target for Prostate Cancer. Reviewed International journal

Itsumi M, Shiota M, Sekino Y, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Kajioka S, Uchiumi T, Eto M:

Prostate   2020.8

Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. Reviewed International journal

Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, Shinohara N; Japanese Urological Oncology Group, Fukuda H:

Cancer Sci   2020.7

Surgical Navigation Improves Renal Parenchyma Volume Preservation in Robot-Assisted Partial Nephrectomy: A Propensity Score-matched Comparative Analysis. Reviewed International journal

Kobayashi S, Cho B, Mutaguchi J, Inokuchi J, Tatsugami K, Hashizume M, Eto M:

J Urol   2020.7

Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer. Reviewed International journal

Shiota M, Fujimoto N, Yamamoto Y, Takeuchi A, Tatsugami K, Uchiumi T, Matsuyama H, Eto M:

Cancer Immunol Immunother   2020.7

Postinjury Bladder Overdistension Deteriorates the Lower Urinary Tract's Storage Function in Patients with Spinal Cord Injury. Reviewed International journal

Takahashi R, Kimoto Y, Maki T, Eto M:

Urol Int   2020.6

Tadalafil Improves Nocturia and Nocturia-Related Quality of Life in Patients With Benign Prostatic Hyperplasia (KYU-PRO Study). Reviewed International journal

Takahashi R, Sumino Y, Miyazato M, Nishii H, Oshiro T, Mimata H, Saito S, Yoshida M, Eto M:

Urol Int   2020.6

The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator. Reviewed International journal

Kashiwagi E, Abe T, Kinoshita F, Ushijima M, Masaoka H, Shiota M, Netto GJ, Eto M, Miyamoto H:

Am J Transl Res   2020.6

Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper. Reviewed International journal

Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H:

Int J Urol   2020.5

Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Reviewed International journal

Noguchi M, Arai G, Egawa S, Ohyama C, Naito S, Matsumoto K, Uemura H, Nakagawa M, Nasu Y, Eto M, Suekane S, Sasada T, Shichijo S, Yamada A, Kakuma T, Itoh K:

Cancer Immunol Immunother   2020.5

Programmed Death Ligand 1/indoleamine 2,3-dioxygenase 1 Expression and Tumor-Infiltrating Lymphocyte Status in Renal Cell Carcinoma With Sarcomatoid Changes and Rhabdoid Features. Reviewed International journal

Kiyozawa D, Takamatsu D, Kohashi K, Kinoshita F, Ishihara S, Toda Y, Eto M, Oda Y:

Hum Pathol   2020.4

A Prediction Model of Detrusor Underactivity Based on Symptoms and Noninvasive Test Parameters in Men with Lower Urinary Tract Symptoms: An Analysis in a Large Group of Patients Undergoing Pressure-flow Studies. Reviewed International journal

Namitome R, Takei M, Takahashi R, Kikutake C, Yokomizo A, Yamaguchi O, Eto M:

J Urol   2020.4

Family history in primary hormone therapy for prostate cancer: Analysis from a community-based multi-institutional Japan-wide database. Reviewed International journal

Shiota M, Onozawa M, Hinotsu S, Eto M, Naito S, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):

Int J Urol   2020.4

Thick perirenal fat predicts the growth pattern of renal cell carcinoma. Reviewed International journal

Kashiwagi E, Imada K, Abe T, Kinoshita F, Monji K, Shiota M, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:

Kidney Cancer   2020.3

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. Reviewed International journal

Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, Uemura H, Choueiri TK, Motzer RJ, Fujii Y, Kamei Y, Umeyama Y, di Pietro A, Oya M:

Cancer Sci   2020.3

Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study. Reviewed International journal

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:

Anticancer Drugs   2020.3

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer. Reviewed International journal

Kashiwagi E, Shiota M, Masaoka H, Imada K, Monji K, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:

Prostate Int   2020.3

Contractile elements and their sympathetic regulations in the pig urinary bladder: a species and regional comparative study. Reviewed International journal

Mitsui R, Lee K, Uchiyama A, Hayakawa S, Kinoshita F, Kajioka S, Eto M, Hashitani H:

Cell Tissue Res   2020.2

Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel. Reviewed International journal

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:

Anticancer Res   2020.1

Nonischemic or Ischemic Laparoscopic Partial Nephrectomy Using a Newly Developed Hybrid Energy Device in a Porcine Model. Reviewed International journal

Tanaka M, Irie S, Nakagawa K, Nishimatsu H, Inokuchi J, Eto M:

J Endourol   2020.1

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer. Reviewed International journal

Hirata Y, Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:

Prostate Int   2019.12

Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. Reviewed International journal

Kuroiwa K, Inokuchi J, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yokomizo A, Matsuyama H, Ichikawa T, Mizusawa J, Eba J, Naito S; Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG):

J Urol   2019.12

Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer. Reviewed International journal

Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:

Urol Oncol   2019.11

Psoas muscle volume is correlated with sexual activity and erectile dysfunction among patients with localised prostate cancer. Reviewed International journal

Kashiwagi E, Imada K, Monji K, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M:

Andrologia   2019.10

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. Reviewed International journal

Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G:

Int J Clin Oncol   2019.9

Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study. Reviewed International journal

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:

Cancer Chemother Pharmacol   2019.9

Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study. Invited Reviewed International journal

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:

Anticancer Res   2019.8

Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program. Reviewed International journal

Kume H, Homma Y, Shinohara N, Obara W, Kondo T, Kimura G, Fujimoto H, Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M:

Jpn J Clin Oncol   2019.8

TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease. Reviewed International journal

Baba M, Furuya M, Motoshima T, Lang M, Funasaki S, Ma W, Sun HW, Hasumi H, Huang Y, Kato I, Kadomatsu T, Satou Y, Morris N, Karim BO, Ileva L, Kalen JD, Wilan Krisna LA, Hasumi Y, Sugiyama A, Kurahashi R, Nishimoto K, Oyama M, Nagashima Y, Kuroda N, Araki K, Eto M, Yao M, Kamba T, Suda T, Oike Y, Schmidt LS, Linehan WM:

Mol Cancer Res   2019.8

Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Reviewed International journal

Tanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D, Kinoshita F, Akiba J, Kashiwagi E, Takeuchi A, Irie T, Tatsugami K, Hoshino T, Eto M, Nishikawa H:

Clin Cancer Res   2019.8

Assessment of surgical skills by using surgical navigation in robot-assisted partial nephrectomy. Reviewed International journal

Kobayashi S, Cho B, Huaulmé A, Tatsugami K, Honda H, Jannin P, Hashizumea M, Eto M:

Int J Comput Assist Radiol Surg   2019.8

Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer. Reviewed International journal

Akitake M, Yamaguchi A, Shiota M, Imada K, Tatsugami K, Yokomizo A, Naito S, Eto M:

Anticancer Res   2019.8

Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy. Reviewed International journal

Shiota M, Ushijima M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Eto M:

Prostate   2019.7

Papillary renal cell carcinoma with massive hematoma mimicking hemangioma. Reviewed International journal

Hiraki Y, Okamoto D, Nishie A, Asayama Y, Ishigami K, Ushijima Y, Takayama Y, Fujita N, Eto M, Kinoshita F, Honda H:

Radiol Case Rep   2019.6

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study. Reviewed International journal

Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M, Uemura H:

Jpn J Clin Oncol   2019.6

Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. Reviewed International journal

Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer:

Cancer Sci   2019.6

Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men. Reviewed International journal

Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:

Clin Genitourin Cancer   2019.6

MicroRNA‐204‐5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. Reviewed International journal

Kurahashi R, Kadomatsu T, Baba M, Hara C, Itoh H, Miyata K, Endo M, Morinaga J, Terada K, Araki K, Eto M, Schmidt LS, Kamba T, Linehan WM, Oike Y:

Cancer Sci   2019.6

Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer. Reviewed International journal

Kobayashi T, Namitome R, Hirata YU, Shiota M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:

Anticancer Res   2019.6

The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men. Reviewed International journal

Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:

Cancer Chemother Pharmacol   2019.5

Overview of current and future systemic therapy for metastatic renal cell carcinoma. Reviewed International journal

Osawa T, Takeuchi A, Kojima T, Shinohara N, Eto M, Nishiyama H:

Jpn J Clin Oncol   2019.5

Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle. Reviewed International journal

Maki T, Kajioka S, Itsumi M, Kareman E, Lee K, Shiota M, Eto M:

Low Urin Tract Symptoms   2019.4

Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Reviewed International journal

Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ:

Future Oncol   2019.3

Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer. Reviewed International journal

Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M:

Urol Oncol   2019.3

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer. Reviewed International journal

Shiota M, Namitome R, Kobayashi T, Inokuchi J, Tatsugami K, Eto M:

Int J Urol   2019.3

Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study. Reviewed International journal

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:

Med Oncol   2019.2

Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. Reviewed International journal

Harada K, Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G, Fujisawa M, Nonomura N, Eto M, Shinohara N, Tomita Y, Kondo Y, Ochi K, Anazawa Y, Uemura H:

Int J Urol   2019.2

Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. Reviewed International journal

Umezu D, Okada N, Sakoda Y, Adachi K, Ojima T, Yamaue H, Eto M, Tamada K:

Cancer Immunol Immunother   2019.2

Reconstitution of the embryonic kidney identifies a donor cell contribution to the renal vasculature upon transplantation. Reviewed International journal

Murakami Y, Naganuma H, Tanigawa S, Fujimori T, Eto M, Nishinakamura R:

Sci Rep   2019.2

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone. Reviewed International journal

Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M:

JAMA Netw Open   2019.2

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy. Reviewed International journal

Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:

Front Oncol   2018.12

Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer. Reviewed International journal

Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M:

Andrologia   2018.12

Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan. Reviewed International journal

Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T:

Clin Genitourin Cancer   2018.12

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Reviewed International journal

Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI:

Ann Oncol 29   2018.12

Clinical factors affecting perioperative outcomes in robot-assisted radical prostatectomy. Reviewed International journal

Murakami T, Otsubo S, Namitome R, Shiota M, Inokuchi J, Takeuchi A, Kashiwagi E, Tatsugami K, Eto M:

Mol Clin Oncol 9 (5): 575-581, 2018   2018.11

Long-term urodynamic follow-up after external sphincterotomy in patients with spinal cord injury. Reviewed International journal

Takahashi R, Kimoto Y, Eto M:

Neurourol Urodyn   2018.11

Clinicopathological Significance and Antitumor Effect of MPHOSPH1 in Testicular Germ Cell Tumor. Reviewed International journal

Abe T, Kohashi K, Takemoto J, Kinoshita F, Eto M, Oda Y:

J Cancer   2018.10

Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants. Reviewed International journal

Shiota M, Dejima T, Yamamoto Y, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:

Cancer Sci   2018.10

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone. Reviewed International journal

Akitake N, Shiota M, Obata H, Takeuchi A, Kashiwagi E, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:

Prostate Int   2018.9

Metyrapone-responsive ectopic ACTH-secreting pheochromocytoma with a vicious cycle via a glucocorticoid-driven positive-feedback mechanism. Reviewed International journal

Inoue M, Okamura K, Kitaoka C, Kinoshita F, Namitome R, Nakamura U, Shiota M, Goto K, Ohtsubo T, Matsumura K, Oda Y, Eto M, Kitazono T:

Endocr J   2018.7

Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer. Reviewed International journal

Murakami T, Obata H, Akitake N, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Eto M:

Anticancer Res   2018.7

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Reviewed International journal

Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I:

Oncotarget   2018.7

A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases. Reviewed International journal

Akitake M, Kiyoshima K, Yokomizo A, Shiga K, Koga H, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Yamaguchi A, Eto M:

Mol Clin Oncol   2018.6

Comparison of the diagnostic efficacy and perioperative outcomes of limited versus extended pelvic lymphadenectomy during robot-assisted radical prostatectomy: a multi-institutional retrospective study in Japan. Reviewed International journal

Morizane S, Honda M, Fukasawa S, Komaru A, Inokuchi J, Eto M, Shimbo M, Hattori K, Kawano Y, Takenaka A:

Int J Clin Oncol   2018.6

実臨床に有用な後腹膜腫瘍の特徴 －第19回九州泌尿器科共同研究　九州沖縄地区における後腹膜腫瘍の実態調査サブ解析－． Reviewed

藤本直浩、守屋良介、岩隈景子、久保達彦、久岡正典、野口　満、有働和馬、内藤誠二、江藤正俊、横溝　晃、三股浩光、澁谷忠正、賀本敏行、分田裕順、井川　掌、西原聖顕、酒井英樹、竹原浩介、計屋知彰、中川昌之、山根隆史、神波大己、河野吉昭、斎藤誠一、安次嶺　聡、大城吉則、田中正利、古屋隆三郎、石井　龍：

西日泌尿   2018.3

The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer. Reviewed International journal

Shiota M, Fujimoto N, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M:

J Urol   2018.3

Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR. Reviewed International journal

Reix B, Bernhard JC, Patard JJ, Bigot P, Villers A, Suer E, Vuong NS, Verhoest G, Alimi Q, Beauval JB, Benoit T, Nouhaud FX, Lenormand C, Hamidi N, Cai J, Eto M, Larre S, El Bakhri A, Ploussard G, Hung A, Koutlidis N, Schneider A, Carrouget J, Droupy S, Marchal S, Doerfler A, Seddik S, Matsugasumi T, Orsoni X, Descazeaud A, Pfister C, Bensalah K, Soulie M, Gill I, Flamand V; Kidney Cancer group of the CCAFU:

Prog Urol   2018.3

Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy. Reviewed International journal

Takeuchi A, Kato K, Akashi K, Eto M:

Int J Urol   2018.2

Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro. Reviewed International journal

Tsuruta M, Ueda S, Yew PY, Fukuda I, Yoshimura S, Kishi H, Hamana H, Hirayama M, Yatsuda J, Irie A, Senju S, Yuba E, Kamba T, Eto M, Nakayama H, Nishimura Y:

Oncoimmunology   2018.1

Demographics, management and treatment outcomes of benign and malignant retroperitoneal tumors in Japan. Reviewed International journal

Fujimoto N, Kubo T, Hisaoka M, Udo K, Yokomizo A, Shibuya T, Wakeda H, Nishihara K, Moriya R, Iwakuma K; Kyushu Cooperative Urological Research Group:

Int J Urol   2018.1

Role of K+ channels in regulating spontaneous activity in the muscularis mucosae of guinea pig bladder. Reviewed International journal

Lee K, Isogai A, Antoh M, Kajioka S, Eto M, Hashitani H:

Eur J Pharmacol   2018.1

Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study). Reviewed International journal

Takahashi R, Miyazato M, Nishii H, Sumino Y, Takayama K, Onzuka M, Oshiro T, Saito S, Fujimoto N, Mimata H, Eto M:

Low Urin Tract Symptoms   2018.1

Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Reviewed International journal

Hara T, Fujimoto H, Kondo T, Shinohara N, Obara W, Kimura G, Kume H, Nonomura N, Hongo F, Sugiyama T, Kanayama HO, Takahashi M, Fukumori T, Eto M; Cancer Registration Committee of the Japanese Urological Association.

Jpn J Clin Oncol   2017.12

Alcohol consumption and bladder cancer risk with or without the flushing response: The Japan Public Health Center-based Prospective Study. Reviewed International journal

Masaoka H, Matsuo K, Sawada N, Yamaji T, Goto A, Shimazu T, Iwasaki M, Inoue M, Eto M, Tsugane S; Japan Public Health Center-based Prospective Study Group:

Int J Cancer   2017.12

Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity. Reviewed International journal

Matsumoto T, Uchiumi T, Monji K, Yagi M, Setoyama D, Amamoto R, Matsushima Y, Shiota M, Eto M, Kang D:

Oncogenesis   2017.11

Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A. Invited Reviewed International journal

Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Asano T, Mizusawa J, Eba J, Naito S:

World J Urol   2017.11

Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer. Reviewed International journal

Obata H, Shiota M, Akitake N, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:

Anticancer Res   2017.10

An In Vitro Study of a New Device: Evaluation of Novel Wide-Angle Lens Flexible Cystoscope Using Phantom Bladder Model. Reviewed International journal

Yamaguchi K, Inoue T, Habuchi T, Inokuchi J, Yokomizo A, Eto M, Kanayama HO:

J Endourol   2017.10

Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models. Reviewed International journal

Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M:

Cancer Sci   2017.10

Aldehyde Dehydrogenase 2 Polymorphism Is a Predictor of Smoking Cessation. Reviewed International journal

Masaoka H, Gallus S, Ito H, Watanabe M, Yokomizo A, Eto M, Matsuo K:

Nicotine Tob Res   2017.9

Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan. Reviewed International journal

Masaoka H, Ito H, Yokomizo A, Eto M, Matsuo K:

Cancer Sci   2017.8

Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment. Reviewed International journal

Yanagihara T, Tanaka K, Ota K, Kashiwagi E, Takeuchi A, Tatsugami K, Eto M, Nakanishi Y, Okamoto I:

Ann Oncol   2017.8

Impact of lymph node dissection on clinical outcomes during nephroureterectomy in patients with clinically node-negative upper urinary tract urothelial cancer: subanalysis of a multi-institutional nationwide case series of the Japanese Urological Association. Reviewed International journal

Inokuchi J, Eto M, Hara T, Fujimoto H, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T, Ohyama C; Cancer Registration Committee of the Japanese Urological Association:

Jpn J Clin Oncol   2017.7

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. Reviewed International journal

Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, Motzer RJ, Uemura H, McHenry MB, Berghorn E, Ozono S:

Jpn J Clin Oncol   2017.7

Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy. Reviewed International journal

Sato N, Shiota M, Shiga KI, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Koga H, Yamaguchi A, Naito S, Eto M:

Jpn J Clin Oncol   2017.5

The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer. Reviewed International journal

Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Yokomizo A, Eto M:

Ann Surg Oncol   2017.5

Protein kinase C regulates Twist1 expression via NF-κB in prostate cancer. Reviewed International journal

Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:

Endocr Relat Cancer   2017.4

Combination of ALDH2 and ADH1B polymorphisms is associated with smoking initiation: A large-scale cross-sectional study in a Japanese population. Reviewed International journal

Masaoka H, Ito H, Gallus S, Watanabe M, Yokomizo A, Eto M, Matsuo K:

Drug Alcohol Depend   2017.4

A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Reviewed International journal

Obara W, Eto M, Mimata H, Kohri K, Mitsuhata N, Miura I, Shuin T, Miki T, Koie T, Fujimoto H, Minami K, Enomoto Y, Nasu T, Yoshida T, Fuse H, Hara I, Kawaguchi K, Arimura A, Fujioka T:

Ann Oncol   2017.4

Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress. Reviewed International journal

Shiota M, Fujimoto N, Itsumi M, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M:

Ann Oncol   2017.3

Reality of nerve sparing and surgical margins in surgeons' early experience with robot-assisted radical prostatectomy in Japan. Reviewed International journal

Tatsugami K, Yoshioka K, Shiroki R, Eto M, Yoshino Y, Tozawa K, Fukasawa S, Fujisawa M, Takenaka A, Nasu Y, Kashiwagi A, Gotoh M, Terachi T; Japanese Society of Endourology:

Int J Urol   2017.3

FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer. Reviewed International journal

Imada K, Shiota M, Kuroiwa K, Sugimoto M, Abe T, Kohashi K, Yokomizo A, Eto M, Naito S, Oda Y:

Prostate   2017.2

Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor. Reviewed International journal

Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J, Tatsugami K, Eto M:

J Urol   2017.2

Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes. Reviewed International journal

Bigot P, Bernhard JC, Flamand V, Gill I, Verhoest G, Beauval JB, Nouhaud FX, Suer E, Ploussard G, Hetet JF, Rigaud J, Baco E, Larré S, Sebe P, Koutlidis N, Descazeaud A, Eto M, Doerfler A, Roupret M, Vuong NS, Reix B, Matsugasumi T, Bakri AE, Albiges L, Soulié M, Patard JJ, Méjean A, Bensalah K; members of the Kidney Cancer group of the CCAFU:

Urol Oncol   2017.1

PD-L1 expression in papillary renal cell carcinoma. Reviewed International journal

Motoshima T, Komohara Y, Ma C, Dewi AK, Noguchi H, Yamada S, Nakayama T, Kitada S, Kawano Y, Takahashi W, Sugimoto M, Takeya M, Fujimoto N, Oda Y, Eto M:

BMC Urol   2017.1

Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare. Reviewed International journal

Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Shiga KI, Koga H, Yamaguchi A, Naito S, Eto M

BJU Int   2016.12

C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy. Reviewed International journal

Wada Y, Maeda Y, Kubo T, Kikuchi K, Eto M, Imamura T

Oncol Lett   2016.11

Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer. Reviewed International journal

Shiota M, Yokomizo A, Takeuchi A, Inokuchi J, Tatsugami K, Ohga S, Sasaki T, Nakamura K, Honda H, Eto M

Jpn J Clin Oncol   2016.10

ロボット手術時代における前立腺癌リンパ節転移予測ノモグラムの妥当性． Reviewed International journal

猪口 淳一, 波止 亮, 清島 圭二郎, 武内 在雄, 塩田 真己, 高橋 良輔, 立神 勝則, 横溝 晃, 江藤 正俊

西日泌尿   2016.9

Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan. Reviewed International journal

Takahashi S, Hamasuna R, Yasuda M, Ishikawa K, Hayami H, Uehara S, Yamamoto S, Minamitani S, Kadota J, Iwata S, Eto M, et al.

J Infect Chemother   2016.9

Effects of switching from alpha-blocker to tadalafil in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (KYU-PRO STUDY). Reviewed International journal

Miyazato M, Oshiro T, Saito S, Takahashi R, Eto M, Nishi H, Fujimoto N, Sumino Y, Miyata H, Arai K, Kinjo T

Nishinihon J Urol   2016.8

Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2. Reviewed International journal

Itsumi M, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Naito S, Eto M, Yokomizo A

Cancer Sci   2016.7

Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy. Reviewed International journal

Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K,, Nakamura T, Ogawa O, Naito S

Cancer Sci   2016.7

The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism. Reviewed International journal

Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M

Prostate Cancer Prostatic Dis   2016.6

Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer. Reviewed International journal

Takeuchi　A, Eto M, Tatsugami K, Shiota M, Yamada H, Kamiryo Y, Dejima T, Kashiwagi E, Kiyoshima K, Inokuchi J, Takahashi R, Yokomizo A, Ohara N, Yoshikai Y

Int Immunopharmacol   2016.6

Aldehyde dehydrogenase 2 (ALDH2) and alcohol dehydrogenase 1B (ADH1B) polymorphisms exacerbate bladder cancer risk associated with alcohol drinking: gene-environment interaction. Reviewed International journal

Masaoka H, Ito H, Soga N, Hosono S, Oze I, Watanabe M, Tanaka H, Yokomizo A, Hayashi N, Eto M, Matsuo K

Carcinogenesis   2016.6

Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Reviewed International journal

Koie T, Ohyama C, Fujimoto H, Nishiyama H, Miyazaki J, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T, Cancer Registration Committee of the Japanese Urological Association, Ohyama C, Nishiyama H, Fujisawa M, Uemura H, Fujimoto H, Suzuki K, Eto M, et al.

Jpn J Clin Oncol   2016.5

Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma. Reviewed International journal

Ma C, Komohara Y, Ohnishi K, Shimoji T, Kuwahara N, Sakumura Y, Matsuishi K, Fujiwara Y, Motoshima T, Takahashi W, Yamada S, Kitada S, Fujimoto N, Nakayama T, Eto M, Takeya M

Cancer Sci   2016.5

Impact of multimodal treatment on prognosis for patients with metastatic upper urinary tract urothelial cancer: Subanalysis of the multi-institutional nationwide case series study of the Japanese Urological Association. Reviewed International journal

Inokuchi J, Seiji Naito, Fujimoto H, Hara T, Sakura M, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T, Ohyama C, Cancer Registration Committee of the Japanese Urological Association

Int J Urol   2016.3

Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Reviewed International journal

Shiota M, Eto M

Int J Urol   2016.3

CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma. Reviewed International journal

Motoshima T, Komohara Y, Horlad H, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M

Oncol Lett   2016.3

The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. Reviewed International journal

Bigot P, Bernhard JC, Gill IS, Vuong NS, Verhoest G, Flamand V, Reix B, Suer E, Gökce I, Beauval JB, Nouhaud FX, Eto M, et al.

World J Urol   2016.3

Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer. Reviewed International journal

Kiyoshima K, Akitake M, Shiota M, Takeuchi A, Takahashi R, Inokuchi J, Tatsugami K, Yokomizo A, Eto M

Anticancer Res   2016.2

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy. Reviewed International journal

Shiota M, Yokomizo A, Eto M

Front Oncol   2016.1

An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. Reviewed International journal

Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S, Ohyama C, Nasu Y, Tanaka M, Moriya F, Suekane S, Matsueda S, Komatsu N, Sasada T, Yamada A, Kakuma T, Itoh K

Clin Cancer Res   2016.1

Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association. International journal

Hara T, Fujimoto H, Sakura M, Inokuchi J, Nishiyama H, Miyazaki J, Ohyama C, Koie T, Kikuchi E, Hinotsu S, Cancer Registration Committee of the Japanese Urological Association

Int J Urol   2015.11

Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: Subanalysis of the Japanese Urological Association multi-institutional national database. International journal

Miyazaki J, Nishiyama H, Fujimoto H, Ohyama C, Koie T, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T, Cancer Registration Committee of the Japanese Urological Association

Int J Urol   2015.11

Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan. International journal

Eto M, Kawano Y, Hirao Y, Mita K, Arai Y, Tsukamoto T, Hashine K, Matsubara A, Fujioka T, Kimura G, Shinohara N, Tatsugami K, Hinotsu S, Naito S, Japan RCC Trialist Collaborative Group (JRTCG) investigators

BMC Cancer   2015.10

Clinicopathological characteristics and oncological outcomes in patients with renal cell carcinoma registered in 2007: The first large-scale multicenter study from the Cancer Registration Committee of the Japanese Urological Association. International journal

Kanayama HO, Fukumori T, Fujimoto H, Nakanishi H, Ohyama C, Suzuki K, Nishiyama H, Eto M, Miki T, Kamoi K, Kubota Y, Takahashi S, Homma Y, Naito S

Int J Urol   2015.9

Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma. International journal

Naito S, Sakai H, Hashine K, Tomita Y, Shinohara N, Fujisawa M, Eto M, Ozono S, Akaza H

Ann Oncol   2015.9

Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era. International journal

Tatsugami K, Shinohara N, Kondo T, Yamasaki T, Eto M, Tsushima T, Terachi T, Naito S, Japanese Society of Renal Cancer

Int J Urol   2015.8

Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells. International journal

Motoshima T, Komohara Y, Horlad H, Takeuchi A, Maeda Y, Tanoue K, Kawano Y, Harada M, Takeya M, Eto M

Oncol Rep   2015.6

C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. International journal

Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, Kikuchi K, Imamura T, Eto M

Oncol Rep   2015.4

IJU this issue. International journal

Eto M

Int J Urol   2015.3

Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation. International journal

Takeuchi　A, Eto M, Tatsugami K, Yamada H, Yokomizo A, Shiota M, Itsumi M, Inokuchi J, Kiyoshima K, Dejima T, Imada K, Naito S, Yoshikai S

Transpl Immunol   2015.3

Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation.

Hamaguchi M, Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Teshima T, Harada M, Yoshikai Y, Naito S:

Cancer Sci   2009.1

What affects the results of a laparoscopic adrenalectomy for pheochromocytoma? Evaluation with respect to intraoperative blood pressure and state of tumor.

Tatsugami K, Eto M, Hamaguchi M, Yokomizo Y, Harano M, Naito S:

J Endourol   2009.1

小径腎癌に対する腎部分切除術の有用性・安全性の検討－根治的腎摘除術との比較－.

原野正彦、江藤正俊、濱口益光、立神勝則、上領頼之、内藤誠二：

西日泌尿   2008.11

Dendritic cell therapy in combination with interferon-α for the treatment of metastatic renal cell carcinoma.

Tatsugami K, Eto M, Harano M, Hamaguchi M, Miyamoto T, Morisaki T, Furue M,　Akashi K, Naito S:

Int J Urol   2008.8

The efficacy of laparoscopic radical nephrectomy for renal cell cancer in the elderly: an oncological outcome analysis.

Harano M, Eto M, Yokomizo A, Tatsugami K, Hamaguchi M, Naito S:

Int J Urol   2008.7

Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.

Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Harada M, Kiyoshima K, Hamaguchi M, Teshima T, Tsuneyoshi M, Yoshikai Y, Naito S:

Clin Cancer Res   2008.5

Laparoscopic adrenalectomy for malignant tumors.

Eto M, Hamaguchi M, Harano M, Yokomizo A, Tatsugami K, Naito S:

Int J Urol   2008.4

Broadcast of live endoscopic surgery from Korea to Japan using the digital video transport system.

Eto M, Lee TY, Gill IS, Koga H, Tatsugami K, Shimizu S, Ukimura O, Naito S:

J Endourol   2007.12

Comparison of standard and hand-assised laparoscopic radical nephrectomy for renal cell carcinoma.

Harano M, Eto M, Yokomizo A, Tatsugami K, Hamaguchi M, Naito S:

Fukuoka Acta Med   2007.11

STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.

Ito N, Eto M, Nakamura E, TakahashiA, Tsukamoto T, Toma H, Nakazawa H, Hirao Y, Uemura H, Kagawa S, Kanayama H, Nose Y, Kinukawa N, Nakamura T, Jinnai N, Seki T, Takamatsu M, Masui Y, Naito S, Ogawa O:

J Clin Oncol   2007.7

Training of robotic surgery in Kyushu University Hospital.

Eto M, Ieiri S, Tanoue K, Hashizume M, Naito S:

Recent Advances in Endourology Proceedings of the 3rd Annual Meeting of EASE 10:   2007.4

A pilot study of the assessment of the quality of life, functional results, and complications in patients with an ileal neobladder for invasive bladder cancer.

Harano M, Eto M, Nakamura M,　Hasegawa Y, Kano M, Yamaguchi A, Naito S:

Int J Urol   2007.2

Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease.

Eto M, Harano M, Tatsugami K, Harada M, Kamiryo Y, Kiyoshima K, Hamaguchi M, Tsuneyoshi M, Yoshikai Y, Naito S:

Clin Cancer Res   2007.2

回腸利用代用膀胱造設術の日常生活QOL・術後合併症・oncological outcome・腎機能推移について－cutaneous diversion症例との比較検討－.

原野正彦、江藤正俊、甲斐信幸、内藤誠二、中村元信、長谷川淑博、山口秋人、加野資典：

西日泌尿   2006.10

Clinical outcomesand learning curve of a laparoscopic adrenalectomy in 103 consecutive cases at a single institute.

Eto M, Harano M, Koga H, Tanaka M, Naito S:

Int J Urol   2006.6

In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.

Ichikura H, Eto M, Ueno H,Harada M, Takayama K, Tokuda N, Tatsugami K, Naito S:

Oncol Rep   2006.5

Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells.

Eto M, J Bennouna, OC Hunter,MT Lotze, AA Amoscato:

Int J Urol   2006.2

The change of the split renal function before and after a nephrectomy using Tc-mercaptoacetyltriglycine (MAG3).

Harano M, Tokuda N, Ichikura H, Nakamura M,Eto M, Tatsugami K, Naito S:

Fukuoka Acta Med   2005.12

Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice.

Harano M, Eto M, Iwai T, Tatsugami K, Kiyoshima K, Kamiryo Y, Tsuneyoshi M, Yoshikai Y, Naito S:

Cancer Res   2005.11

Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guerin for superficial bladder tumors.

Eto M, Koga H, Noma H, Yamaguchi A, Yoshikai Y, Naito S:

Urol Int   2005.9

Long-term outcome of hand-assisted laparoscopic radical nephrectomy for localized stage T1/T2 renal-cell carcinoma.

Harano M, Eto M, Omoto K, Tatsugami K, Nomura H, Koga H, Hojyo M,Yamaguchi A, Naito S:

J Endourol   2005.9

Anti-tumour activity of heat-shock protein 60-recognizing CD4+ T cells against syngeneic murine renal cell carcinoma.

Eto M, Harada M,Tatsugami K, Harano M, Koga H, Matsuzaki G,Naito S:

BJU Int   2005.2

Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines.

Tsunoda T, Koga H, Yokomizo A, Tatsugami K, Eto M, Inokuchi J, Hirata A, Masuda K, Okumura K, Naito S:

Oncogene   2005.2

診断率向上のための方策　1) 到達法について.

尾本和也、増田克明、平田　晃、江藤正俊、横溝　晃、古賀寛史、内藤誠二：

腎泌予防医誌   2005.1

Chemical shift MR imaging を用いた腎癌の診断－clear call carcinomaにおける胞体内脂肪検出の試みについて.

尾本和也、江藤正俊、徳田倫章、立神勝則、原野正彦、内藤誠二、吉満研吾、本田　浩：

西日本泌尿器科   2004.5

マウス腎癌に対する特異的、非特異的免疫の検討.

立神勝則、江藤正俊、一倉晴彦、尾本和也、原野正彦、古賀寛史、内藤誠二：

腎癌研究会会報   2004.4

手術支援ロボット''ZEUS''の腹腔鏡下根治的前立腺摘除術への応用－泌尿器科手術におけるロボット手術の現状と展望－.

江藤正俊、横溝　晃、古賀寛史、角田俊之、内藤誠二：

Japanese Journal of Endourology and ESWL   2004.2

ハンドアシスト法による腹腔鏡下ドナー腎摘出術.

江藤正俊、徳田倫章、原野正彦、尾本和也、田中正利、内藤誠二：

Japanese Journal of Endourology and ESWL   2004.1

腎盂尿管腫瘍に対するハンドアシスト法を用いた後腹膜鏡下腎尿管全摘除術.

尾本和也、江藤正俊、内藤誠二：

Japanese Journal of Endourology and ESWL   2004.1

九州大学泌尿器科学教室における1999年から2001年の3年間の臨床統計.

江頭稔久、後藤　健、中村元信、坂本直孝、徳田倫章、阪口　岳、志賀健一郎、宗　裕賢、根岸孝仁、平賀紀行、堀　幹史、結城康平、内野洋志、上領頼之、加野雅子、清島圭二郎、友田稔

西日泌尿   2003.9

C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. Reviewed International journal

Eto M, Bennouna J, Hunter OC, Hershberger PA, Kanto T, Johnson CS, Lotze MT, Amoscato AA.

Prostate   2003.9

進行腎癌に対する Interferon-α、5-fluorouracil、UFT、Leucovorin、Cimetidine 併用療法.

江藤正俊、徳田倫章、尾本和也、一倉晴彦、原野正彦、内藤誠二

腎癌研究会会報   2003.1

Promotion of skin graft tolerance across MHC barriers by mobilization of dendritic cells in donor hemopoietic cell infusions. Reviewed International journal

Eto M, Hackstein H, Kaneko K, Nomoto K, Thomson AW.

J. Immunol   2002.9

腎細胞癌に対するハンドアシスト法による腹腔鏡下根治的腎摘除術.

田中正利、北条守文、江藤正俊、野間秀哉、野村博之、山口秋人、内藤誠二

日鏡外会誌   2002.6

腎癌の臨床における血管新生因子群の有用性とVEGF受容体を標的とした遺伝子治療.

徳田 倫章、中村 元信、江藤 正俊、一倉 晴彦、中島 信能、古賀 寛史、内藤 誠二、坂本 泰二、上野 光

西日泌尿   2001.4

Cyclophosphamide-induced tolerance in rat orthotopic liver transplantation. Reviewed International journal

Okano S, Eto M, Tomita Y, Yoshizumi T, Yamada H, Minagawa R, Nomoto K, Sugimachi K, Nomoto K.

Transplantation   2001.2

Antitumor activity of interleukin-12 against murine bladder cancer. Reviewed International journal

Eto M, Harada M, Tamada K, Tokuda N, Koikawa Y, Nakamura M, Nomoto K, Naito S.

J. Urol   2000.5

腎癌術後の経過観察に血中血管新生因子測定は果たして有用か.

徳田 倫章、中村 元信、江藤 正俊、内藤 誠二

腎癌研究会会報   2000.1

造影CT上広範なlow density areaを伴う腎細胞癌の臨床的特徴.

徳田倫章、中村元信、江藤正俊、鯉川弥須宏、内藤誠二:

腎癌研究会会報   1999.4

Importance of intrathymic mixed chimerism for the maintenance of skin allograft tolerance across fully allogeneic antigens in mice.

Eto M, Kong Y-Y, Uozumi J, Naito S, Nomoto K:

Immunology   1999.3

カテーテルフリーにできなかった頚髄損傷患者の臨床的検討.

分田 裕順、岩坪 暎二、江藤 正俊、井上 幸広、長田 幸夫

西日泌尿   1999.1

Regulatory T cells in maintenance and reversal of peripheral tolerance in vivo. International journal

KongY-Y, Eto M, Omoto K, Umesue M, Hashimoto A, Nomoto K

J Immunol   1996.12

Sensitization of T cell receptor-αβ+ T cells recovered from long-term T cell receptor-downmodulation. International journal

Omoto K, Y-Y Kong, Nomoto K, Umesue M, Murakami Y, Eto M, Nomoto K

Immunology   1996.6

Role of the transversus perinei profundus muscle on voiding: the meaning of UPmax in patients with paralyzed urethral sphincter. International journal

Iwatsubo E, Sakamoto Y, Eto M, Kumazawa J

Neurourol Urodyn   1996.1

The induction of skin xenograft tolerance in rat-to-mouse combination could be affected by DFR mediating cells and antibodies against rat bone marrow cells as well as NK cells in the cyclophosphamide-induced tolerance system. International journal

Nishimura Y, Eto M, Maeda T, Hiromatsu K, Nomoto K, Y-Y Kong, Nomoto K

Immunobiol   1995.8

Prolongation of kidney graft survival by cyclophosphamide-induced tolerance in rats. International journal

Eto M, Nishimura Y, Matsuo K, Omoto K, Goto K, Kumazawa J, Nomoto K

J Urol   1995.5

Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-T cell receptor antibody. International journal

Maeda T, Eto M, T Lin, Nishimura Y, Y-Y Kong, Nomoto K

J Immunol   1994.11

Inhibition of skin xenograft rejetion by depleting T-cell receptor αβ-bearing cells without T-cell receptor γδ-bearing cells or natural killer cells by monoclonal antibody. International journal

Nishimura Y, Eto M, Maeda T, Hiromatsu K, Kobayashi N, Nomoto K, Y-Y Kong, Nomoto K

Immunology   1994.10

Importance of intrathymic mixed chimerism for maintenace of skin allograft tolerance aross fully allogeneic (entire major H-2 plus multiminor histocompatibility) antigen barriers in mice. International journal

Eto M, Nishimura Y, Y-Y Kong, Maeda T, Nomoto K, Kumazawa J, Nomoto K

Transplant Proc   1994.4

Exacerbation of established collagen-induced arthritis in mice treated with an anti-T cell receptor antibody. International journal

Maeda T, Saikawa I, Hotokebuchi T, Sugioka Y, Eto M, Murakami Y, Nomoto K

Arthritis & Rheumatism   1994.3

Evidence that donor-specific suppressor T cells can be produced indepently of the thymus. International journal

Maeda T, Eto M, Nishimura Y, Y-Y Kong, Nomoto K, Nomoto K

Transplantation   1994.2

Inhibition of allograft rejection by anti-T-cell receptor-αβ monoclonal antibodies preserving resistance to bacterial infection. International journal

Eto M, Yoshikai Y, Nishimura Y, Hiromatsu K, Maeda T, Nomoto K, Y-Y Kong, Kubo RT, Kumazawa J, Nomoto K

Immunology   1994.2

外傷性脊髄麻痺.

岩坪 暎二、江藤 正俊、分田 裕順、井上 幸広

臨床と研究   1994.1

CICの現状と問題点脊損患者の自己導尿：適応拡大の工夫を中心に.

岩坪 暎二、江藤 正俊、分田 裕順、井上 幸広

日本パラプレジア医学会雑誌   1994.1

神経因性膀胱のVURに対する膀胱尿管新吻合術.

山下 博志、玉田 耕治、木元 康介、原岡 正志、熊澤 淨一、岩坪 暎二、井上 幸広、岡田 英一郎、竹原 俊幸、江藤 正俊

西日泌尿   1994.1

脊損者の腎尿管結石治療−外科手術は許されない時代か？−.

江藤 正俊、岩坪 暎二、分田 裕順、井上 幸広

日本パラプレジア医学会雑誌   1994.1

脊損者の腎尿管結石治療　外科手術とESWLの比較検討.

江藤 正俊、岩坪 暎二、分田 裕順、井上 幸広、山口 秋人、鷺山 和幸、原 三信

西日泌尿   1994.1

神経因性膀胱の尿失禁に対する手術療法の試み.

岩坪 暎二、江藤 正俊、分田 裕順、井上 幸広

西日泌尿   1994.1

Role of peripheral hemopoietic chimerism in achieving donor-specific tolerance in adult mice. International journal

Maeda T, Eto M, Nishimura Y, Nomoto K, Y-Y Kong, Nomoto K

J Immunol   1993.2

Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming. International journal

Maeda T, Eto M, Nishimura Y, Nomoto Y, Y-Y Kong, Nomoto K

Immunology   1993.1

第2章　泌尿器腫瘍 　C．腎がん 　　4．免疫チェックポイント阻害薬 　　5．免疫チェックポイント阻害薬＋チロシンキナーゼ阻害薬　6．サイトカイン療法

後藤駿介、江藤正俊：

中外医学社，東京  2022.7 

日本泌尿器科学会、日本病理学会、日本医学放射線学会編： 泌尿器科・病理・放射線科 前立腺癌取扱い規約 第5版

前立腺癌取扱い規約作成委員会（第5版）： 頴川　晋、髙橋　悟、市川智彦、上村博司、浮村　理、江藤正俊、小川　修 賀本敏行、久米春喜、小島祥敬、鈴木和浩、武中　篤、那須保友、舛森直哉 赤松秀輔、井上貴博、河原崇司、木村高弘、塩田真己、橋本浩平、秦　淳也 藤原敦子、都築俊介：

メディカルレビュー社，大阪  2022.5 

日本泌尿器科学会、日本病理学会、日本医学放射線学会、日本臨床腫瘍学会編： 腎盂・尿管・膀胱癌取扱い規約 第2版

腎盂・尿管・膀胱癌取扱い規約作成委員会（第2版）： 西山博之、髙橋　悟、野々村祝夫、江藤正俊、大山　力、藤元博行、羽渕友則 松山豪泰、原　勲、篠原信雄、藤本清秀、菊地栄次、河合弘二、木村友和 都築豊徳、南口早智子、宮居弘輔、陣﨑雅弘、扇谷芳光、三浦裕司、松原伸晃 中川昌之、金山博臣、那須保友、高橋俊二、新本　弘、村田晋一、有田祐起:

医学図書出版, 東京  2021.8 

第Ⅲ編　泌尿器科の主な手術 　第20章　開放手術.

江藤正俊：

2021.3 

腎細胞癌，腎血管筋脂肪腫. /今日の治療指針 私はこう治療している

江藤正俊：

医学書院, 東京  2021.1 

日本泌尿器科学会、日本病理学会、日本医学放射線学会編：泌尿器科・病理・放射線科　腎癌取扱い規約 第5版

腎癌取扱い規約作成委員会（第5版）: 篠原信雄、髙橋　悟、大家基嗣、藤井靖久、久米春喜、近藤恒徳、冨田善彦 木村　剛、高橋正幸、江藤正俊、舛森直哉、神波大己、水野隆一、田中　一 山名一寿、立神勝則、大澤崇宏:

メディカルレビュー社，大阪  2020.12 

9章　内視鏡手術（泌尿器）.

江藤正俊、小林　聡、牟田口　淳、今田憲二郎：

コロナ社, 東京  2020.11 

Ⅶ 泌尿・生殖器腫瘍 　④前立腺 　　Q2　高齢の前立腺がん患者に対する標準的外科治療の治療成績はどうか？

門司恵介、江藤正俊：

金原出版株式会社, 東京  2020.10 

第2章　泌尿器腫瘍 　Ｃ．腎がん 　　4．免疫チェックポイント阻害薬 　　5．免疫チェックポイント阻害薬＋チロシンキナーゼ阻害薬　6．サイトカイン療法

梅津大輔、江藤正俊：

中外医学社，東京  2020.9 

前立腺癌. /今日の治療指針 私はこう治療している

江藤正俊：

2020.1 

第4章　泌尿器科　腎がん. /内科 124 (3) 増大号: 内科医に求められる他科の知識　専門家が伝える Do/Don't

今田憲二郎、江藤正俊：

2019.9 

日本泌尿器科学会編： 膀胱癌診療ガイドライン2019年版

膀胱癌診療ガイドライン2019年版作成委員会： 松山豪泰、中川昌之、猪口淳一、都築豊徳、藤本清秀、藤井靖久、北村　寛、篠原信雄、江藤正俊、植村天受、西山博之、小川　修、井上啓史、菊地栄次、大山　力、藤元博行、東　治人、羽渕友則、溝脇尚志、鳴海善文、樋之津史郎、髙橋　悟：

医学図書出版, 東京  2019.9 

日本癌治療学会、日本病理学会編： 領域横断的がん取扱い規約第1版

領域横断的癌取扱い規約検討委員会 泌尿器科・病理・放射線科 腎癌取扱い規約／副腎腫瘍取扱い規約／泌尿器科・病理・放射線科 腎盂・尿管・膀胱癌取扱い規約／泌尿器科・病理・放射線科 前立腺癌取扱い規約／精巣腫瘍取扱い規約 担当委員：江藤正俊、猪口淳一、今田憲二郎

金原出版, 東京  2019.9 

1．腎癌 　ニボルマブ（イピリムマブとの併用を含む）. /泌尿外 (32) 特別号:これ一冊でパーフェクト‼ 泌尿器科薬物療法

門司恵介、江藤正俊：

2019.4 

日本臨床腫瘍学会編： がん免疫療法ガイドライン 第2版

日本臨床腫瘍学会 がん免疫療法ガイドライン改訂版作成ワーキンググループ（WG）： 馬場英司、勝俣範之、赤松弘朗、有安宏之、池田公史、今川彰久、宇原　久、江藤正俊、北園　聡、北野滋久、鈴木重明、玉田耕治、鳥越俊彦、廣中秀一、福原規子、藤原　豊、朴　成和、室　圭、山本信之、横田知哉：

金原出版, 東京  2019.3 

血精液症. /今日の治療指針 私はこう治療している

江藤正俊：

医学書院, 東京  2019.1 

Ⅲ．Risk factor up to date～リスク分類と1次治療選択～ 　2．オピニオンリーダーに訊く 　　5) IMDCリスク分類と1次治療選択 /Year Book of RCC 2018

江藤正俊、今田憲二郎：

メディカルレビュー社, 大阪  2018.12 

男性がかかるがんの第3位 前立腺がん． /差がつく70歳からの病気 サインと最新治療

監修：江藤正俊、東　治人：

2018.5 

Ⅲ．腎癌治療 up to date 　１．分子標的薬の新たな展開 　　3) 新しい分子標的薬 /Year Book of RCC 2017

出嶋　卓、江藤正俊：

メディカルレビュー社, 大坂  2018.1 

Ⅴ．転移性膀胱癌 　3．immuno-oncologyの現状 /膀胱癌診療最前線

出嶋　卓、江藤正俊：

株式会社メジカルビュー社, 東京  2017.12 

Ⅱ．検診・診断 　Q9．わが国における前立腺癌検診の現状と，理想的な検診とは？ /Q＆Aでスッキリわかる 前立腺癌

柏木英志、江藤正俊：

メジカルビュー社，東京  2017.8 

§16．泌尿器科疾患 　6．男性生殖器 　　§16-36．精巣上体炎、精巣炎 /1336専門家による私の治療 2017-18年度版

甲斐信幸、江藤正俊：

日本医事新報社，東京  2017.7 

日本泌尿器科学会編： 腎癌診療ガイドライン2017年版

大園誠一郎、原　勲、篠原信雄、金山博臣、冨田善彦、長嶋洋治、江藤正俊、樋之津史郎、三宅秀明、杉山貴之：

メディカルレビュー社，東京  2017.7 

Ⅰ．RCC Bench to Bedside～基礎研究の最前線～ 　2．癌の不均一性と進化・進展． /Year Book of RCC 2016

馬場理也、江藤正俊：（Role：Joint author）

メディカルレビュー社, 大坂  2017.1 

腸管利用尿路変向術とそのケア. /今日の治療指針 私はこう治療している

江藤正俊：

医学書院, 東京  2017.1 

Ⅲ．治療方針・治療法 Ｇ．泌尿器科領域の注目すべき疾患と治療の進歩 5. 腎腫瘍 /腎疾患・透析 最新の治療 2017-2019

出嶋　卓、江藤正俊：（Role：Joint author）

南江堂, 東京  2017.1 

Ⅴ．転移性膀胱癌 　immuno-oncologyの現状 /膀胱癌診療最前線

出嶋　卓、江藤正俊：

株式会社メジカルビュー社, 東京  2016.12 

前立腺がん. /週刊朝日MOOK 手術数でわかるいい病院2016

江藤 正俊, 東 治人：（Role：Joint author）

朝日新聞出版, 東京  2016.2 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Kidney Cancer Asia Consensus Statements Version 3

Ozono S, Umbas R, Akaza H, Cheng JCH, Chung BH, Gupta N, Hinotsu S, Horie S, Kim CS, Kwak C, Kwong PWK, Lee JY, Lojanapiwat B, Namiki M, Eto M, et al.（Role：Joint author）

NCCN ACS secretariat, Reno Medical K.K., Tokyo  2016.1 

腎がん. /名医の最新治療2016

藤澤 正人, 江藤 正俊：（Role：Joint author）

朝日新聞出版, 東京  2015.11 

Ⅴ．婦人科がん，泌尿生殖器がん D. 腎細胞がん 15．腎細胞がんに対してサイトカイン療法は推奨されるか？

河野 吉昭, 江藤 正俊：（Role：Joint author）

中外医学社, 東京  2015.10 

I．前立腺癌 5　前立腺癌原発病巣の量的・質的診断法としてのMRIの位置づけは？〜特に手術療法における有用性について〜

谷川 史城, 江藤 正俊：（Role：Joint author）

中外医学社, 東京  2015.4 

腎癌に対する細胞免疫療法－LAK療法から樹状細胞療法、ミニ移植まで－について教えて下さい.回答.

立神勝則、江藤正俊：

中外医学社, 東京  2008.4 

Topics of RCC－薬物療法の最前線－ 分子標的薬 1) Sorafenibをめぐるトピックス.

江藤正俊：

メディカルレビュー社, 大阪,  2008.4 

腎細胞癌に対する細胞療法の展望.

立神勝則、江藤正俊、内藤誠二：

メジカルビュー社, 東京  2007.4 

腎がんの新しい治療法 2) その他の新しい治療法.

江藤正俊、内藤誠二：

医薬ジャーナル社, 東京  2007.4 

腎細胞癌.

江藤正俊：

2006.4 

遠隔手術.

江藤正俊、内藤誠二：

2006.4 

7 新しい手術器具・機器 4 遠隔手術.

江藤正俊、内藤誠二：

2005.4 

Robotic surgery assisted by the ZEUS system.

Eto M, Naito S:

2004.4 

Hand-assisted laparoscopic radical nephrectomy for renal cancer.

Tanaka M, Hojo M, Eto M, Noma H, Nomura H, Yamaguchi A, Naito S:

2003.4 

ロボット手術とテレサージェリー.

江藤正俊、内藤誠二：

2003.4 

表在性膀胱癌に対するBCG注入療法.

江藤正俊：

2002.4 

Optimization of extended pelvic lymph node dissection side for prostate cancer.

Shiota M, Shimbo M, Tsukahara S, Tanegashima T, Mutaguchi J, Goto S, Kobayashi S, Matsumoto T, Hattori K, Endo F, Eto M

40th Annual EAU congress 2025  2025.3 

Artificial Intelligence system for detecting flat bladder tumors in cystoscopic images. International conference

Mutaguchi J, Oda M, Tokiyoshi T, Tsukahara S, Goto S, Kobayashi S, Matsumoto T, Shiota M, Mori K, Eto M

40th Annual EAU congress 2025  2025.3 

Cancer vaccine to overcome resistance of immune checkpoint inhibitors. International conference

Ueda S, Irie A, Senju S, Ito K, Hamana H, Udaka K, Kishi H, Ogasawara K, Nishimura Y, Eto M

40th Annual EAU congress 2025  2025.3 

A retrospective study of the association between oral 5-ALA and hypotension in patients with bladder cancer undergoing TURBT. International conference

Goto S, Tanegashima T, Tsukahara S, Mutaguchi J, Kobayashi S, Matsumoto T, Shiota M, Eto M

40th Annual EAU congress 2025  2025.3 

進行性腎細胞癌におけるアベルマブ+アキシチニブ併用療法の実臨床成績;日本における多施設共同後ろ向き長期観察研究 (J-DART2).

加藤大悟、江藤正俊他

第22回日本臨床腫瘍学会学術集会  2025.3 

正常腎ネフロン内の変異プロセスの多様性.

家入康輔、垣内伸之、渡部光一、川口　駿、後藤駿介、松元　崇、井元清哉、塩田真己、小川誠司、江藤正俊

第34回泌尿器科分子・細胞研究会  2025.2 

膀胱内再発を来す腎盂尿管癌における原発巣免疫微小環境の解析.

伊藤大輔、種子島時祥、奥村元紀、板橋耕太、小山正平、西川博嘉、江藤正俊

第34回泌尿器科分子・細胞研究会  2025.3 

膀胱全摘術後に皮膚筋炎が軽快した筋層浸潤性膀胱癌の一例.

満安　正、牟田口　淳 種子島時祥、塚原茂大、後藤駿介、小林　聡、松元　崇、塩田真己、江藤正俊

日本泌尿器科学会福岡地方会第315回例会  2025.2 

非コード領域のホットスポット変異で予測する筋層浸潤性膀胱癌（MIBC）の病勢.

塚原茂大、塩田真己、永川祥平、種子島時祥、牟田口　淳、後藤駿介、小林　聡、松元　崇、兒玉啓補、内海　健、江藤正俊

第9回Liquid Biopsy研究会  2025.2 

ロボット支援術後に横紋筋融解症を呈した症例の検討.

香月東道、松元　崇、種子島時祥、塚原茂大、牟田口　淳、後藤駿介、小林　聡、塩田真己、江藤正俊

第137回日本泌尿器科学会沖縄地方会  2025.2 

筋層浸潤性膀胱癌に対する術前GC療法中に脳梗塞を発症した症例の検討.

重安哲志、後藤駿介、種子島時祥、塚原茂大、牟田口　淳、小林　聡、松元　崇、塩田真己、江藤正俊

日本泌尿器科学会第96回宮崎地方会  2025.1 

前立腺癌および非前立腺癌における前立腺マイクロバイオームの特徴.

岡田達憲、塩田真己、江藤正俊

第39回前立腺シンポジウム  2024.12 

前立腺癌に対する重粒子線治療後のsalvage RARPの治療成績.

塚原茂大、塩田真己、種子島時祥、牟田口　淳、後藤駿介、小林　聡、松元　崇、江藤正俊

第39回前立腺シンポジウム  2024.12 

前立腺外側筋膜温存によるロボット支援前立腺全摘除術後の尿禁制改善効果についての報告.

辻田次郎、塩田真己、塚原茂大、種子島時祥、牟田口　淳、後藤駿介、小林　聡、松元　崇、江藤正俊

第39回前立腺シンポジウム  2024.12 

非筋層浸潤性膀胱癌におけるBCG療法後の再発とMSIの関連.

永川祥平、塩田真己、塚原茂大、牟田口　淳、種子島時祥、後藤駿介、小林　聡、松元　崇、江藤正俊

第7回泌尿器光⼒学研究会・第17回BCG注⼊療法研究会 （合同開催）  2024.12 

根治的前立腺全摘除術後の鼠経ヘルニアについて～AoBアンケートより～.

森實修一、小林　聡、成田伸太郎、藤井　圭、松原猛人、斎藤卓也 、早川俊輔、江藤正俊、羽渕友則、江口　徹 、武中　篤

第37回日本内視鏡外科学会総会  2024.12 

偽被膜を有しない腫瘍に対する工夫 －手術ナビゲーションシステムの活用－.

月野圭治、小林　聡 牟田口　淳、塚原茂大、種子島時祥、後藤駿介、松元　崇、塩田真己、江藤正俊

第37回日本内視鏡外科学会総会  2024.12 

泌尿器科領域における3D画像・VR・MRの現状と将来.

小林　聡、浅野大輔、工藤勇人、成田伸太郎、森實修一、田邉　稔、池田徳彦、江藤正俊

第37回日本内視鏡外科学会総会  2024.12 

ロボット支援膀胱全摘除術の回腸導管造設術におけるECUDとICUDの周術期治療成績.

牟田口　淳、小林　聡、塩田真己、江藤正俊

第37回日本内視鏡外科学会総会  2024.12 

ロボット支援腹腔鏡下前立腺全摘術(RARP)後に発症する鼠径ヘルニアに対する治療を考える.

藤井　圭、松原猛人、斎藤卓也、早川俊輔、門司恵介、小林　聡、成田伸太郎、森實修一、江口　徹、江藤正俊

第37回日本内視鏡外科学会総会  2024.12 

下部尿管癌に対するロボット支援下尿管・膀胱部分切除、膀胱尿管新吻合術の初期経験.

松元　崇、猪口淳一、塚原茂大、種子島時祥、牟田口　淳、後藤駿介、小林　聡、塩田真己、江藤正俊

第38回日本泌尿器内視鏡・ロボティクス学会総会  2024.11 

前立腺癌に対する重粒子線治療後のロボット支援下救済手術.

塚原茂大、塩田真己、種子島時祥、牟田口　淳、後藤駿介、小林　聡、松元　崇、猪口淳一、江藤正俊

第38回日本泌尿器内視鏡・ロボティクス学会総会  2024.11 

腎シンチグラフィを用いたロボット支援腎部分切除術後の患側腎機能の検討.

元　貴彦、牟田口　淳、種子島時祥、塚原茂大、後藤駿介、小林　聡、松元　崇、塩田真己、江藤正俊

第38回日本泌尿器内視鏡・ロボティクス学会総会  2024.11 

鉗子情報を取り入れた手術ナビゲーションシステムの開発.

月野圭治、小林　聡、小栗　晋、牟田口　淳、塚原茂大、種子島時祥、後藤駿介、松元　崇、塩田真己、江藤正俊

第38回日本泌尿器内視鏡・ロボティクス学会総会  2024.11 

前立腺癌に対する拡大骨盤リンパ節郭清側の最適化.

塩田真己、新保正貴、塚原茂大、種子島時祥、後藤駿介、小林　聡、松元　崇、服部一紀、遠藤文康、江藤正俊

第38回日本泌尿器内視鏡・ロボティクス学会総会  2024.11 

免疫チェックポイント阻害薬を含む薬物療法後に手術を施行した腎癌症例の治療成績.

後藤駿介、種子島時祥、塚原茂大、牟田口　淳、小林　聡、松元　崇、塩田真己、江藤正俊

第38回日本泌尿器内視鏡・ロボティクス学会総会  2024.11 

シミュレーションによる核医学治療の待機期間の変化予測と適切な治療提供体制の検討.

溝脇尚志、細野　眞、上村博司、江藤正俊、大家基嗣、三宅秀明、池田公史、金ヶ崎彩子、櫻木俊輔、老田侑平、絹谷清剛

日本放射線腫瘍学会第37回学術大会  2024.11 

腎癌診療における3D画像生成に向けた自動セグメンテーションシステム開発.

小林　聡、月野圭治、牟田口　淳、塚原茂大、種子島時祥、後藤駿介、松元　崇、塩田真己、江藤正俊

第33回日本コンピュータ外科学会大会  2024.11 

Efficacy and Safety of Enfortumab Vedotin for Metastatic Urothelial Carcinoma at Kyushu University. International conference

Shiraishi K, Matsumoto T, Mutaguchi J, Tsukahara S, Tanegashima T, Goto S, Kobayashi S, Shiota M, Eto M

The 40th KOREA-JAPAN Urological Congress  2024.11 

ロボット支援腎部分切除術における鉗子情報を取り入れた術中ナビゲーションシステムの開発.

月野圭治、小林　聡、小栗　晋、牟田口　淳、塚原茂大、種子島時祥、後藤駿介、松元　崇、塩田真己、江藤正俊

第33回日本コンピュータ外科学会大会  2024.11 

尿中cell-free DNA を用いた非筋層浸潤性膀胱癌に対する再発モニタリング.

永川祥平、塚原茂大、牟田口　淳、種子島時祥、後藤駿介、小林　聡 松元　崇、塩田真己、江藤正俊

第76回西日本泌尿器科学会総会  2024.11 

西日本泌尿器科学会をいかに素晴らしい学会にするか.

江藤正俊

第76回西日本泌尿器科学会総会  2024.11 

転移性去勢抵抗性前立腺癌患者におけるアンドロゲン受容体シグナル伝達阻害剤の有効性に対するプロトンポンプ阻害剤の影響.

種子島時祥、塩田真己、塚原茂大、牟田口　淳、後藤駿介、小林　聡、松元　崇、江藤正俊

第76回西日本泌尿器科学会総会  2024.11 

Analysis of Tumor Immune Microenvironment in the Upper Tract Urothelial Carcinoma with Intravesical Recurrence.

伊藤大輔、種子島時祥、板橋耕太、奥村元紀、塚原茂大、牟田口　淳、後藤駿介、小林　聡、松元　崇、塩田真己、小山正平、西川博嘉、江藤正俊

第76回西日本泌尿器科学会総会  2024.11 

リキッドバイオプシーが切り開く泌尿器癌治療の未来.

加藤大悟、松原伸晃、塩田真己、安水洋太、田中伸之、大澤崇宏、安部崇重、小島崇宏、石津谷祐、山本致之、中山雅志、水谷晃輔、三浦裕司、大家基嗣、篠原信雄、江藤正俊、吉野孝之、野々村祝夫

第76回西日本泌尿器科学会総会  2024.11 

当院における前立腺癌に対する重粒子線治療後の救済根治的前立腺全摘術の治療成績.

塚原茂大、塩田真己、種子島時祥、牟田口　淳、後藤駿介、小林　聡、松元　崇、江藤正俊

日本泌尿器腫瘍学会第10回学術集会  2024.10 

cfDNA による非翻訳領域の遺伝子変異評価による膀胱癌病勢予測.

塚原茂大、塩田真己、永川祥平、種子島時祥、牟田口　淳、後藤駿介、小林　聡、松元　崇、江藤正俊

日本泌尿器腫瘍学会第10回学術集会  2024.10 

尿路上皮癌診断における新規尿中バイオマーカー.

猪口淳一、松元　崇、村田正治、河野喬仁、姜　貞勲、塩田真己、江藤正俊

日本泌尿器腫瘍学会第10回学術集会  2024.10 

尿路上皮癌に対するアベルマブ維持療法の初期経験.

松元　崇、牟田口　淳、塚原茂大、種子島時祥、後藤駿介、小林　聡、塩田真己、江藤正俊

第62回日本癌治療学会学術集会  2024.10 

非翻訳領域のホットスポット変異解析による筋浸潤性膀胱癌の病勢評価.

塚原茂大、塩田真己、松元　崇、永川祥平、種子島時祥、牟田口　淳、小林　聡、内海　健、兒玉啓補、江藤正俊

第62回日本癌治療学会学術集会  2024.10 

マウスモデルにおけるがん抗原の同定と難治性がんの克服.

上田翔平、牛島美保、入江　厚、千住　覚、伊藤甲雄、浜名　洋、岸　裕之、小笠原康悦、宇高恵子、西村泰治、江藤正俊

第62回日本癌治療学会学術集会  2024.10 

Accuracy Comparison of Artificial Intelligence Object Detection System in Narrow-band imaging (NBI) Cystoscopic Images. International conference

Mutaguchi J, Oda M,Tanegashima T,Tsukahara S, Goto S, Kobayashi S,Matsumoto T, Shiota M,Mori K, Eto M

KUA 2024 76th Annual Meeting of The Korean Urological Association 

Immune suppression by PD-L2 against treatment-related antitumor immunity in RCC. International conference

Tanegashima T, Tsukahara S, Mutaguchi J, Goto S,Kobayashi S, Matsumoto T, Shiota M, Nishikawa H,Eto M

KUA 2024 76th Annual Meeting of The Korean Urological Association 

ロボット支援腎部分切除術における人工知能を活用したナビゲーションシステムの開発.

月野圭治、小林　聡、牟田口　淳、塚原茂大、種子島時祥、後藤駿介、松元　崇、塩田真己、江藤正俊

第34回九州内視鏡・ロボット外科手術研究会  2024.10 

日本泌尿器科学会による専門医育成方針.

江藤正俊

第89回日本泌尿器科学会東部総会  2024.10 

Independent validation of genetic risk model to progression after intravesical BCG therapy for NMIBC. International conference

Nagakawa S, Shiota M, Tsukahara S, Mutaguchi J, Tanegashima T, Goto S, Kobayashi S, Matsumoto T, Eto M

2024 The 3rd Annual Meeting of KUOS-EAUOS  2024.9 

Analysis of Tumor Immune Microenvironment in the Upper Tract Urothelial Carcinoma with Intravesical Recurrence.

Ito D, Tanegashima T, Okumura G, Itahashi K, Tsukahara S, Mutaguchi J, Goto S, Kobayashi S, Matsumoto T, Shiota M, Koyama S, Nishikawa H, Eto M

第83回日本癌学会学術総会  2024.9 

非筋層浸潤性膀胱癌におけるBCG療法後の進行に対する遺伝子リスクモデルの検証.

永川祥平、塩田真己、塚原茂大、種子島時祥、上田翔平、牟田口　淳、後藤駿介、小林　聡、松元　崇、江藤正俊

第83回日本癌学会学術総会  2024.9 

正常腎における遺伝子解析.

家入康輔、垣内伸之、平野智紀、渡部光一、前田紘奈、田中洋子、高松　大、松元　崇、門司恵介、塩田真己、宮野　悟、江藤正俊、小川誠司

第83回日本癌学会学術総会  2024.9 

ロボット支援腎部分切除術における手術ナビゲーション開発.

月野圭治、小林　聡、小栗　晋、宮内翔子、塩田真己、沖　英次、倉爪　亮、江藤正俊

第57 回九大医工連携イニシアチブ  2024.9 

Clinical outcome of systemic therapy for non-clear cell RCC at our institute in the I-O era. International conference

Goto S, Tanegashima T, Tsukahara S, Mutaguchi J, Kobayashi S, Matsumoto T, Shiota M, Eto M

21th Urological Association of Asia Congress  2024.9 

Development and post-marketing surveillance of a new attachment for L43K ultrasound probe in robot-assisted partial nephrectomy. International conference

Kobayashi S, Nakadate R, Miyata S, Tsukino K, Mutaguchi J, Tanegashima T, Tsukahara S, Goto S, Matsumoto T, Shiota M, Eto M

21th Urological Association of Asia Congress  2024.9 

膀胱平滑筋における環状ヌクレオチドの役割.

岡田達憲、Shahab N 牧　知子、梶岡俊一 江藤正俊

第31回日本排尿機能学会  2024.9 

尿管鏡支援ロボットの実現可能性に向けた開発研究.

小林　聡、正木文太郎 King F、Wollin DA Kibel AS、波多信彦 江藤正俊

日本尿路結石症学会 第34回学術集会  2024.8 

Surgical results of renal cell carcinoma after systemic therapy with immune-checkpoint inhibitors. International conference

Tsujita J, Goto S, Nagakawa S, Ueda S, Tanegashima T, Tsukahara S, Kobayashi S, Matsumoto T, Shiota M,  Eto M

TUA 2024 Annual Meeting  2024.8 

Detection of PLEKHS1 mutation in ctDNA predicts early recurrence compared to CT-scan in muscle-invasive bladder cancer. International conference

Matsumoto T, Tsukahara S, Mutaguchi J, Tanegashima T, Goto S, Kobayashi S, Shiota M, Eto M

TUA 2024 Annual Meeting  2024.8 

Novel Technology in Robotic/Laparoscopic Surgery. International conference

Kobayashi S, Masaki F, King F, Wolin DA, Kibel AS, Hata N, Eto M

WCET 2024 World Congress of Endourology and Uro- Technology  2024.8 

A new attachment for a navigation system using 3D models in robot-assisted partial nephrectomy guides surgeons accurately for the target. International conference

Tsukino K, Kobayashi S, Mutaguchi J, Tsukahara S, Tanegashima T, ​ Goto S, Matsumoto T, Shiota M, Eto M

WCET 2024 World Congress of Endourology and Uro- Technology  2024.8 

New attachment for L43K ultrasound probe to improve usability in intraoperative laparoscopic ultrasonography for robot-assisted partial nephrectomy.

Kobayashi S, Nakadate R, Miyata S, Tsukino K, Mutaguchi J, Tanegashima T, Tsukahara S, Goto S, Matsumoto T, Shiota M, Eto M

WCET 2024 World Congress of Endourology and Uro- Technology  2024.8 

左副腎衝突腫瘍の1例.

白石航一、牟田口　淳、種子島時祥、塚原茂大、後藤駿介、小林　聡、松元　崇、塩田真己、江藤正俊

第11回JSURT（泌尿器画像診断・治療技術研究会）  2024.8 

当院でのI-O時代における非淡明細胞型腎癌に対する薬物療法の治療成績.

後藤駿介、種子島時祥、塚原茂大、牟田口　淳、小林　聡、松元　崇、塩田真己、江藤正俊

第54回腎癌研究会  2024.7 

当院における完全埋没型腫瘍に対するロボット支援腎部分切除術の治療成績.

牟田口　淳、種子島時祥、塚原茂大、後藤駿介、小林　聡、松元　崇、塩田真己、江藤正俊

第54回腎癌研究会  2024.7 

九州大学泌尿器科学教室における2023年の臨床統計.

辻田次郎、種子島時祥、塚原茂大、牟田口　淳、後藤駿介、小林　聡、松元　崇、塩田真己、江藤正俊

日本泌尿器科学会福岡地方会第314回例会  2024.7 

ACTH産生前立腺小細胞癌の一例.

藤本雄史、種子島時祥、塚原茂大、牟田口　淳、後藤駿介、小林　聡、松元　崇、塩田真己、江藤正俊

日本泌尿器科学会福岡地方会第314回例会  2024.7 

MRI/ultrasound fusion-targeted生検を併用したsystematic前立腺生検の有用性についての検討.

種子島時祥、塩田真己、Blas L、塚原茂大、牟田口　淳、後藤駿介、小林　聡、松元　崇、江藤正俊

第33回日本腎泌尿器疾患予防医学研究会  2024.7 

当院におけるロボット支援腹腔鏡下膀胱全摘除術の治療成績.

牟田口　淳、種子島時祥、塚原茂大、後藤駿介、小林　聡、松元　崇、塩田真己、江藤正俊

第21回泌尿器科再建再生研究会  2024.6 

腎部分切除によって診断された転移性甲状腺濾胞癌の一例.

塚原茂大、牟田口　淳、後藤駿介、小林　聡、松元　崇、門司恵介、塩田真己、猪口淳一、江藤正俊

第36回日本内分泌外科学会総会  2024.5 

80歳以上の高齢者における膀胱全摘術の周術期成績および周術期合併症の予後因子に関する検討－多施設共同研究－.

牟田口　淳、猪口淳一、富崎一向、今村亮一、賀本敏行、鑪野秀一、村上洋嗣、澁谷忠正、野口　満、江藤正俊

第37回日本老年泌尿器科学会  2024.5 

ctDNA detection of non-cording mutation in PLEKHS1 by digital PCR enables early prediction of recurrence in muscle-invasive bladder cancer. International conference

Matsumoto T, Tsukahara S, Mutaguchi J, Tanegashima T, Goto S, Kobayashi S, Shiota M, Eto M

AUA 2024 Annual Meeting  2024.5 

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts).

Tsuchiya N, Gupta S, Climent Durán MÁ, Sridhar SS, Powles T, Bellmunt J, Tyroller K, Guenther S, Eto M, di Pietro A, Grivas P

第111回日本泌尿器科学会総会  2024.4 

Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): analyses by 1L chemotherapy and overall survival (OS) from start of 1L chemotherapy.

Eto M, Sridhar SS, Powles T, Gupta S, Climent Durán MÁ, Aragon-Ching JB, Sternberg CN, Cislo P, Costa N,, di Pietro A, Tsuchiya N, Bellmunt J, Grivas P

第111回日本泌尿器科学会総会  2024.4 

Accuracy Comparison of Object Detection System in NBI Cystoscopic Images.

Mutaguchi J, Oda M, Goto S, Kobayashi S, Matsumoto T, Shiota M, Inokuchi J, Mori K, Eto M

第111回日本泌尿器科学会総会  2024.4 

Genomic characterization of metastatic patterns by circulating tumor DNA in prostate cancer: SCRUM-Japan MONSTAR SCREEN project.

Shiota M, Matsubara N, Kato T, Eto M, Abe T, Shinohara N, Nishimoto K, Tanaka N, Oya M, Fujisawa T, Nakamura Y, Yoshino T, Nonomura N

第111回日本泌尿器科学会総会  2024.4 

Real-world outcomes of avelumab + axitinib therapy in patients with advanced renal cell carcinoma in Japan: a long-term follow-up retrospective study (J-DART2).

Eto M, Kato T, Furukawa J, Hinata N,Ueda K, Hara I, Hongo F, Mizuno R,Okamoto T,Okuno H, Ito T, Kajita M, Uemura H

第111回日本泌尿器科学会総会  2024.4 

Comparison of testosterone level of seminal vesicle fluid in patients with prostate cancer versus other malignancies.

Kashiwagi E, Shiota M, Inokuchi J, Tsukahara S, Monji K, Goto S, Matsumoto T, Eto M

第111回日本泌尿器科学会総会  2024.4 

Cabozantinib or axitinib for second-line treatment after nivolumab plus ipilimumab? ～from JUOG multicenter retrospective real-world data～.

Tomida R, Matsushita Y, Yamana K, Kandori S, Nakano Y, Hara I, Taniguchi H, Eto M, Takagi T, Kojima T, Kitamura H, Miyake H, Takahashi M

第111回日本泌尿器科学会総会  2024.4 

Salvage robot-assisted surgery after carbon ion radiotherapy to the prostate cancer.

Tsukahara S, Shiota M, Takamatsu D, Tanegashima T, Ueda S, Goto S, Kobayashi S, Matsumoto T, Inokuchi J, Shioyama Y, Eto M

第111回日本泌尿器科学会総会  2024.4 

Genomic Alteration and Clinical Significance of Circulating Tumor DNA in Patients with Advanced Urothelial Cancer: SCRUM-Japan MONSTAR SCREEN Project.

Osawa T, Matsubara N, Kato T, Abe T, Shinohara N, Shiota M, Eto M, Nishimoto K, Oya M, Fujisawa T, Nakamura Y, Yoshino T, Nonomura N

第111回日本泌尿器科学会総会  2024.4 

Elucidation of physiological function of human seminal vesicle smooth muscle.

Okada T, Okabe A, Mitsui R, Hashitani H, Kajioka S, Eto M

第111回日本泌尿器科学会総会  2024.4 

Independent validation of genetic risk model to progression after intravesical BCG therapy for NMIBC.

Nagakawa S, Shiota M, Tsukahara S, Matsumoto T, Inokuchi J, Eto M

第111回日本泌尿器科学会総会  2024.4 

Development of an automatic segmentation system for 3D image generation in renal cancer treatment.

Kobayashi S, Tsukino K, Mutaguchi J, Goto S, Matsumoto T, Shiota M, Inokuchi J, Eto M

第111回日本泌尿器科学会総会  2024.4 

Immunophenotype analysis of tumor-infiltrating immune cells to elucidate the mechanism of antitumor effect of IL-7 and CCL19 producing CAR-T cells.

Goto S, Tamada K, Eto M

第111回日本泌尿器科学会総会  2024.4 

Analysis of ctDNA hotspot mutations in non-coding lesion improves early prediction of recurrence in muscle-invasive bladder cancer (MIBC). International conference

Tsukahara S, Shiota M, Matsumoto T, Monji K, Inokuchi J, Uchiumi T, Eto M

39th Annual EAU congress 2024  2024.4 

Cancer vaccine improves the efficacy of immune checkpoint inhibitor against refractory cancers. International conference

Ueda S, Ushijima M, Irie A, Senju S, Ito K, Hamana H, Udaka K, Kishi H, Ogasawara K, Nishimura Y, Eto M

39th Annual EAU congress 2024  2024.4 

An Innovate Segmentation System by Implementing Dilated Convolution and Red Channel Enhanced Images in Cystoscopic Images. International conference

Mutaguchi J, Morooka K, Goto S, Kobayashi S, Matsumoto T, Shiota M, Inokuchi J, Eto M

39th Annual EAU congress 2024  2024.4 

Physio-pharmacological Mechanisms Underlying Ejaculation in Human Seminal Vesicle. International conference

Kajioka S, Okabe A, Okada T, Shiota M, Inokuchi J, Eto M

39th Annual EAU congress 2024  2024.4 

Effect of HLA genotype on anti-PD-1 antibody treatment for advanced renal cell carcinoma. International conference

Tanegashima T, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Tokunaga S, Eto M

39th Annual EAU congress 2024  2024.4 

A potential tumor-marker from urinary microbiota – focusing on renal cell carcinoma. International conference

Kajioka S, Okabe A, Okada T, Toyoda M, Shiota M, Inokuchi J, Takei M, Yokomizo A, Yoshida A, Eto M

39th Annual EAU congress 2024  2024.4 

Characteristics of metastaticrenal cell carcinoma via circulating tumor DNA: Nationwide SCRUM-Japan MONSTAR SCREEN study.

加藤大悟、松原伸晃、石津谷　祐、山本致之、塩田真己、江藤正俊、安水洋太、田中伸之、大家基嗣、大澤崇宏、安部崇重、篠原信雄、西本紘嗣郎、小島崇宏、林　拓自、中山雅志、藤澤孝夫、中村能章、吉野孝之、野々村祝夫

第21回日本臨床腫瘍学会学術集会  2024.2 

尿中cell-free DNAを用いた非筋層浸潤性膀胱癌に対する再発モニタリング.

永川祥平、塩田真己、塚原茂大、松元　崇、門司恵介、猪口淳一、江藤正俊

第33回泌尿器科分子・細胞研究会  2024.2 

正常腎におけるクローン構造の解明.

家入康輔、垣内伸之、高松　大、松元　崇、門司恵介、井元清哉、塩田真己、猪口淳一、小川誠司、江藤正俊

第33回泌尿器科分子・細胞研究会  2024.2 

Highly complex tumorに対するロボット支援腎部分切除術後の腎シンチグラムを用いた患側腎機能に関する検討.

武富昭典、牟田口　淳、後藤駿介、小林　聡、松元　崇、門司恵介、塩田真己、猪口淳一、江藤正俊

第16回日本ロボット外科学会学術集会  2024.2 

当院におけるロボット支援腎尿管全摘除術の初期経験.

門司恵介、牟田口　淳、後藤駿介、小林　聡、松元　崇、塩田真己、猪口淳一、江藤正俊

第16回日本ロボット外科学会学術集会  2024.2 

乳頭型腎細胞癌におけるTFE3の臨床病理学的検討.

高松　大、孝橋賢一、清澤大裕、小林　聡、松元　崇、門司恵介、塩田真己、猪口淳一、小田義直、江藤正俊

第12回日本泌尿器病理研究会（JSUP）学術集会  2024.2 

副腎 primary pigmented nodular adrenocortical diseaseの一例.

松隈啓人、後藤駿介、牟田口　淳、小林　聡、松元　崇、門司恵介、塩田真己、猪口淳一、江藤正俊

日本泌尿器科学会福岡地方会第313回例会  2024.2 

リキッドバイオプシーを用いた尿路上皮癌の診断.

猪口淳一、永川祥平、塩田真己、江藤正俊

第8回Liquid Biopsy研究会  2024.2 

Cell-free DNA(cfDNA)のhotspot解析による筋層浸潤膀胱癌（MIBC）の再発予測.

塚原茂大、塩田真己、内海　健、松元　崇、永川祥平、兒玉啓補、門司恵介、猪口淳一、江藤正俊

第8回Liquid Biopsy研究会  2024.2 

尿中cell-free DNAを用いた非筋層浸潤性膀胱癌に対する再発モニタリング.

永川祥平、塩田真己、塚原茂大、松元　崇、門司恵介、猪口淳一、江藤正俊

第8回Liquid Biopsy研究会  2024.2 

Significance of CD73/adenosine receptor 2 (A2aR) and immune microenvironmental status in renal cell carcinoma with sarcomatoid changes and rhabdoid features. International conference

Takamatsu D, Eto M

2024 Genitourinary Cancers Symposium（ASCO-GU）  2024.1 

Real world experience of FGFR gene alterations and clinical outcomes in advanced/metastatic urothelial cancer in Japan: MONSTAR-SCREEN database study. International conference

Matsubara N, Osawa T, Abe T, Oya M, Nishimoto K, Iwahori T, Tsuchiya H, Murota M, Yoshida M, Tatematsu Y, Nakano Y, Eto M, Nonomura N

2024 Genitourinary Cancers Symposium（ASCO-GU）  2024.1 

転移性腎細胞患者に対するイピリムマブ・ニボルマブ療法おける予後因子に関する検討.

門司恵介、上田翔平、江藤正俊

第36回日本バイオセラピィ学会学術集会総会  2023.12 

PIRADsカテゴリーと臨床的意義のある前立腺癌の検出成績.

塚原茂大、塩田真己、Blas L、牟田口　淳、後藤駿介、松元　崇、門司恵介、猪口淳一、江藤正俊

第38回前立腺シンポジウム  2023.12 

ロボット支援根治的膀胱全摘術における尿路変更術式の比較検討.

魚住友治、牟田口　淳、小林　聡、門司恵介、塩田真己、猪口淳一、江藤正俊

第36回日本内視鏡外科学会総会  2023.12 

ロボット支援膀胱全摘除術後の回腸導管造設術におけるECUDとICUDの周術期成績比較―多施設共同研究より.

猪口淳一、五反田丈徳、三好邦和、澁谷忠正、富崎一向、村上洋嗣、横溝　晃、鑪野秀一、清島圭二郎、江藤正俊

第36回日本内視鏡外科学会総会  2023.12 

ソフトギヤを用いた自走式大腸内視鏡ロボットの開発.

大澤啓介、段　凱文、上田昭夫、中楯　龍、荒田純平、長尾吉泰、赤星朋比古、江藤正俊、田中英一郎

第32回日本コンピュータ外科学会大会  2023.12 

ロボット支援手術内視鏡画像から3D臓器モデル画像を出力する画像変換モデルの構築.

月野圭治、宮内翔子、小林　聡、小栗　晋、牟田口　淳、塚原茂大、後藤駿介、松元　崇、門司恵介、塩田真己、猪口淳一、沖　英次、倉爪　亮、江藤正俊

第32回日本コンピュータ外科学会大会  2023.12 

L43K超音波プローブアタッチメント開発における市販後調査.

小林　聡、中楯　龍、宮田信一、月野圭治、牟田口　淳、後藤駿介、門司恵介、塩田真己、猪口淳一、江藤正俊

第32回日本コンピュータ外科学会大会  2023.12 

当院における 5-アミノレブリン酸による血圧低下に関する検討.

池之上　俊、牟田口　淳、後藤駿介、小林　聡、松元　崇、門司恵介、塩田真己、猪口淳一、江藤正俊

第6回泌尿器光⼒学研究会/第16回BCG注⼊療法研究会 （合同開催）  2023.11